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Abstract 
Human muscle metabolism, the biochemical reactions which to lead storage and 
usage of energy, is complex, but important in understanding human health and 
disease.  Optimal muscle metabolism can help maintain a healthy organism by 
adequately storing and utilizing energy for subsequent use in contraction and 
recovery and adaption from contraction and exercise.  Dysregulated muscle 
metabolism can lead to insulin resistance and obesity among other health 
problems.   
 
 
vi 
Flux balance analysis (FBA) and constraint-based modeling have successfully 
elucidated important aspects of metabolism in single-celled organisms.  However, 
limited work has been done with multicellular organisms.  The foci of this 
dissertation are (1) to show how novel applications of this technique can aid in the 
investigation of human nutrition and (2) to elucidate metabolic phenotypes 
associated with the insulin resistance (IR) characteristics of Type 2 Diabetes 
(T2D). 
First, for human nutrition a novel steady-state constraint-based model of skeletal 
muscle tissue was constructed to investigate the effect of amino acid 
supplementation on protein synthesis.  Several in silico supplementation strategies 
implemented showed that amino acid supplementation could increase muscle 
contractile protein synthesis, which is consistent with published data on protein 
synthesis.  These results suggest that increasing bioavailability of methionine, 
arginine, and the branched-chain amino acids can increase the flux of contractile 
protein synthesis. 
Second, the cause(s) of the altered muscle metabolism in IR remain(s) unknown.  
Attempting to elucidate this complexity, systematic perturbations of the metabolic 
network identified reactions which mimic IR phenotypes.  Reduced flux through a 
single reaction is not sufficient to recapitulate the IR phenotypes, but knockdowns 
in pyruvate dehydrogenase in combination with either reduced lipid uptake or 
lipid/amino acid oxidative metabolism do so.  These combinations also decrease 
complete lipid oxidation and glycogen storage. 
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Introduction 
Human muscle metabolism, the biochemical reactions which lead to storage and 
usage of energy, is complex, but important in understanding human health and 
disease.  Optimal muscle metabolism can help maintain a healthy organism by 
adequately storing and utilizing energy for subsequent use in contraction and 
recovery and adaption from contraction and exercise.  Dysregulated muscle 
metabolism can lead to insulin resistance and obesity among other health 
problems.  However, given the complexities and redundancy of human 
metabolism, it is often difficult, time-consuming, inefficient, and expensive to fully 
investigate hypotheses.  However, with recent advances in metabolic modeling, 
one is now more able to study multiple hypotheses and obtain insight into the entire 
known metabolic network.  Flux Balance Analysis (FBA), a constraint-based 
modeling framework, has been an effective tool at simulating, predicting, and 
elucidating metabolism (Oberhardt et al., 2009;  Cakir et al., 2007; Duarte et al., 
2007; Jerby et al., 2010; Thiele et al., 2013; Folger et al., 2011).  The work 
described in this dissertation showcases a novel metabolic model of muscle 
metabolism and novel applications for and results of FBA: (1) studies into human 
nutrition and (2) investigation into insulin resistance (IR)/Type 2 Diabetes (T2D).  
Specifically, it is used to determine causal relationships between dysregulated 
metabolism leading to diseased phenotypes for the latter, and increasing 
bioavailability of nutrients leading to increased protein synthesis.  Before 
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describing these findings, a short review describes the FBA framework.  This is 
followed by a report of the development of an original metabolic model of human 
skeletal muscle created for use in the work described here.  The next two chapters 
elaborate on novel methodologies and findings which demonstrate how FBA (1) is 
an effective tool for studying human nutrition in the form of amino acid 
supplementation related to post-exercise protein synthesis and (2) provides novel 
approaches in determining causes of metabolic phenotypes specifically related to 
IR and T2D.   The final section contains concluding remarks and broader 
perspectives of the work which will have been presented. 
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Description of Flux Balance Analysis and Model 
Development 
Brief FBA Review 
Flux balance analysis (FBA) (Varma and Palsson, 1994) is a constraint-based 
modeling framework which captures the relationships between input and output 
fluxes associated with biochemical reactions in metabolic networks under different 
conditions and systemic objectives. FBA has been successfully used to model both 
bacterial (Oberhardt et al., 2009) and  human metabolism (Cakir et al., 2007; 
Duarte et al., 2007; Jerby et al., 2010; Thiele et al., 2013; Folger et al., 2011; 
Nogiec and Kasif, 2013).   
FBA models are developed by collating reactions from public databases (e.g. 
KEGG (Kanehisa et al., 2012), BioCyc (Romero et al., 2005)), and by manual 
curation (Nogiec and Kasif, 2013).  These reactions are converted into 
mathematical expressions as a matrix of linear equations (S) where the columns 
represent the set of reactions and the rows represent the set of metabolites.  The 
system is subsequently additionally augmented by linear constraints to increase 
biological feasibility (v).  For example, one can add thermodynamic information by 
constraining the directionality of each reaction (e.g. if irreversible), limit storage of 
metabolites by setting upper limits, and limit substrate availability. These 
constraints are provided as linear inequalities.  This framework provides one with 
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the capability to use modern computational methods to find specific solutions to 
the system of linear equalities and inequalities that optimize a relevant objective 
function.  Objective functions can be manually assigned to represent biological 
objectives of cells.  The model predicts the optimal flux distributions (v), at steady 
state, under specific optimization parameters and perturbations: S * v = 0.  
Optimizing a system of equations with inequalities can lead to multiple solutions 
which satisfy the constraints.  Many techniques have been used to optimize 
prediction accuracy (Segre et al., 2002; Oberhardt et al., 2009).  However, in this 
dissertation, a simplified approach has been used, assuming cells will re-optimize 
after perturbations. 
Model Development 
While there has been an increased attempt to create human tissue specific models 
(Cakir et al., 2007; Shlomi et al., 2008; Jerby et al., 2010; Agren et al., 2012), some 
a subset of the human metabolic model (Duarte et al., 2007), these models are not 
curated, and the authors have not specifically reported on the skeletal muscle 
tissue models (Shlomi et al., 2008; Agren et al., 2012). While the model presented 
in this dissertation is smaller than previously published skeletal muscle models, it 
was built by manually identifying key reactions specific in muscle tissue, similar to 
the method used by Cakir (2007).  This curation process is different than methods 
used by Shlomi et al. (2008) and Agren et al. (2012) which used various algorithms 
incorporating gene expression to predict a tissue specific model from the general 
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human model from Palsson’s lab (Duarte et al., 2007).  One main difference is this 
muscle model includes detailed fluxes for specific muscle proteins (the contractile 
complexes for Type 1, 2a, 2x, and 2b muscle tissue) while the larger models do 
not have these specific reactions. 
 The goal for this model was to capture metabolism from the major macronutrients 
(carbohydrates, lipids, and protein/amino acids) in muscle tissue.  In addition, 
beyond major catabolic reactions, fatty acid and amino acid biosynthesis and 
protein synthesis for the major contractile muscle proteins have been included.  
The flux model developed here combines the previously published flux model of 
the mitochondria (Ramakirshna et al., 2001) with critical additions to uniquely 
capture muscle-specific metabolism: amino acid metabolism, protein synthesis, 
fatty acid oxidation and synthesis, and pentose phosphate metabolism.  For 
example, Aconitase was added (EC 4.2.1.3) which catalyzed the reversible 
reaction between isocitrate and citrate.  In addition, the entire electron transport 
complex (ETC) was modeled, including electron transfer flavoprotein-ubiquinone 
oxidoreductase which oxidizes flavin adenine dinucleotide (EC 1.5.5.1).  Further 
modifications were made to fatty acid oxidation.  The fatty acid used by 
Ramakrishna (2001), palmitate, is a 16 carbon fatty acid.  Although the same 
enzymes are used in each cycle of the fatty acid oxidation, each cycle here is 
detailed.  In other words, there are reactions which oxidize an 18 carbon fatty acid, 
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a 16 carbon fatty acid, etc.  This makes it possible to add other fatty acids as 
substrates and to incorporate amino acid oxidation into the same cycle.  
The model was also expanded to include amino acid and protein metabolism. 
During certain conditions, the muscle will oxidize certain amino acids for energy 
supply (Jungas et al. 1992), and thus amino acids, which are known to be 
metabolized in human muscles, were also included.  The branched-chain amino 
acids (BCAA), isoleucine, leucine, and valine, are used as an energy supply during 
certain conditions, and the byproducts enter fatty acid oxidation cycle and Tri-
Carboxylic Acid (TCA) cycle.  In addition to the BCAAs, serine can be converted 
to pyruvate (EC 4.3.1.17), which can be used in the glycolytic pathway.  The 
oxidative products of lysine also enter the fatty acid oxidation pathway.  Proline 
oxidation produces flavin adenine dinucleotide (FADH), which can be incorporated 
into the electron transport chain (ETC).  The enzymes, which catalyze these 
reactions, were found in the Homo sapiens KEGG pathway map.  Expression in 
muscles of the enzymes was confirmed using UniProt information on tissue 
specificity for each of these enzymes involved in amino acid metabolism.   
In addition to the amino acid metabolism, protein metabolism is included: 
specifically, the synthesis of the major contractile proteins actin, myosin, 
tropomyosin, and troponin.  Their amino acid make-up was determined from NCBI 
database.  Different muscle tissue type expresses different myosin, tropomyosin, 
and troponin.  The myosin complex is made of a heavy chain, which differs 
between type 1/2x, 2a, and 2b muscle types;  a light chain kinase; and a light chain 
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phosphatase.  Tropomyosin is expressed as two sub-types, type 1 and type 2, and 
form dimers within the respective tissue type.  Troponin is composed of three 
subtypes specific to each muscle tissue type 1 or 2: troponin C, troponin I, and 
troponin T. The entire contractile protein complex is composed in the ratio of 7 
actin to 7 myosin to 1 tropomyosin dimer to 1 troponin complex (Gordon et al., 
2000) (Table 1). 
Table 1. Table of the contractile protein complexes in different types 
of muscle tissue 
 
Muscle Type Protein GI (from NCBI) 
Type 1 
Actin 4501881 
Myosin Heavy Chain type 1/2x 115527082 
Myosin Light Chain Kinase 14993776 
Myosin Light Chain 
Phosphatase 
28372499 
Tropomyosin type 1 114155140 
Troponin C type 1 4507615 
Troponin I type 1 56682969 
Troponin T type 1 187173288 
Type 2a 
Actin 4501881 
Myosin Heavy Chain type 2a 153792663 
Myosin Light Chain Kinase 14993776 
Myosin Light Chain 
Phosphatase 
28372499 
Tropomyosin type 2 114155144 
Troponin C type 2 4507617 
Troponin I type 2 4507621 
Troponin T type 2 5803203 
Type 2x 
Actin 4501881 
Myosin Heavy Chain type 1/2x 115527082 
Myosin Light Chain Kinase 14993776 
Myosin Light Chain 
Phosphatase 
28372499 
Tropomyosin type 2 114155144 
Troponin C type 2 4507617 
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Troponin I type 2 4507621 
Troponin T type 2 5803203 
Type 2b 
Actin 4501881 
Myosin Heavy Chain type 1/2x 110611903 
Myosin Light Chain Kinase 14993776 
Myosin Light Chain 
Phosphatase 
28372499 
Tropomyosin type 2 114155144 
Troponin C type 2 4507617 
Troponin I type 2 4507621 
Troponin T type 2 5803203 
 
Nogiec Muscle model v1.0 includes 374 reactions and 341 metabolites (Nogiec 
and Kasif, 2013).  The model is available in standard XML systems biology markup 
language (Nogiec and Kasif, 2013). 
Model Implementation 
Once all the reactions were identified and collected, the text was converted into a 
matrix for use in Mat Lab software package (Version 7.8.0.347 64 bit).  The 
optimization software is the open-source GLPK MatLab interface (Version 4.39): 
©2001-2007, Nicolo’ Giorgetti, which uses linear programming to optimize a 
specified objective function; all default settings were used.  
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A Metabolic Network Framework for Human Nutritional 
Supplements1 
Introduction 
The Nutrition Business Journal (2010) estimates the supplement industry at $23.7 
billion.  However, the claims and efficacy of these supplements are not routinely 
regulated by the Federal Drug Administration.  The question of whether to 
supplement and what to supplement to increase muscle mass has given rise to 
many studies over the years (Blomstrand et al., 2006; Paddonn-Jones et al., 2004; 
Gleeson, 2008).  Much focus has been on protein and amino acid 
supplementation.  However, human studies can be difficult due to small sample 
sizes and length of time per study.  In addition, only a limited number of variables 
can be investigated at a time (i.e., one amino acid or a few combinations at a time).  
Although some results show clear evidence for the efficacy of certain amino acids 
at increasing muscle mass (Blomstrand et al., 2006), others still show inconclusive 
results (Paddonn-Jones et al., 2004; Gleeson, 2008). 
                                            
 
1 This chapter is based on material from the PLOS One publication, “To Supplement or Not to 
Supplement: A Metabolic Network Framework for Human Nutritional Supplements” by Christopher 
D. Nogiec and Simon Kasif (2013).  Both authors have agreed to have the material included in this 
dissertation. 
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One goal of supplementation research in exercise physiology, fitness, and health 
is to determine which metabolites have the biggest effect on increasing muscle 
protein synthesis during the recovery phase.  One method has been to increase 
the bioavailability of amino acids, as these are the building blocks of muscle 
proteins.  Some amino acids and combinations have been investigated in great 
detail.  Branched-chain amino acids (BCAAs) have been shown to increase protein 
synthesis, specifically in muscle tissue, in response to resistance exercise 
(Blomstrand et al., 2006).  Of the three BCAAs, leucine seems to have the most 
prominent effect, and one hypothesis put forth is that leucine may signal an 
increase in enzymes involved in protein synthesis through mammalian target of 
rapamycin (mTOR) (beyond the scope of this introduction) (Blomstrand et al., 
2006).  In addition to the BCAAs, other amino acids have been investigated with 
mixed results.  For example, supplementing with arginine, a conditionally essential 
amino acid, shows that it alone does not seem to increase protein synthesis nor 
does it increase protein synthesis in the presence of the eight essential amino 
acids.  However, some studies indicate that arginine can increase protein 
synthesis in conjunction with other amino acids or with meals (Paddonn-Jones et 
al., 2004).  However, it is unclear which combination of amino acids is most 
beneficial.  Furthermore, many studies show no effect of some amino acids, but 
these amino acids are still highly promoted among nutrition and supplement 
companies.  Glutamine is promoted by supplement manufacturers for numerous 
positive effects, one of which helps muscle protein synthesis.  However, a recent 
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review suggests that glutamine supplementation does not provide any of these 
benefits (Gleeson, 2008). 
It is challenging to determine the individual effects of supplements and their 
combinations in human studies.  Also, without trying every combination, it is 
unclear which are the most beneficial and whether there is a specific combination 
that is most effective.  The advent of metabolic modeling of human tissues opens 
the door to using this platform for studying multiple hypotheses in this space 
including nutrition and supplementation.  Multiple regimes of supplementation can 
be investigated efficiently and predictively. In this dissertation I introduce 
perturbation in the form of additional supplementation and measure the effect of 
individual and combinations of supplements on the protein synthesis flux in the 
model. 
Methods 
Modeling Assumptions 
In addition to assumptions made with FBA (Oberhardt et al., 2009) I add three 
postulates. First, I assume muscle tissue is in a recovery state and primed for 
contractile protein synthesis. For example, the assumption is that all the hormones 
and enzymes available to support protein synthesis are available. In other words, 
this approach investigates an acute response to supplementation.  Next, because 
of the difficulty in obtaining amino acid uptake fluxes for all amino acids into muscle 
tissue, I assume the uptake flux is proportional to amino acid concentration levels, 
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as levels are maintained by the liver and red blood cells (Cynober, 2002; MacLaren 
et al., 2000).  Last, I assume the system reaches a steady state over enough time 
to exhaust the concentrations available in the plasma levels, as the goal is to seek 
qualitative results with this exploratory study. 
Experimental Method 
The goal of the experiment is to determine if supplementation of amino acids above 
a normal, fasting state can improve the protein synthesis flux. The normal fasting 
amino acid profile is based on Cynober (2002) (Table 2). The post-prandial (2 
hours post ingestion of a 200g sirloin steak) is based on the average of Aoki et al. 
(1976), Tessari et al. (1996), and Pozefsky et al. (1969) (Table 1).   
Table 2.   Fasting and Post-prandial control for 
glucose, fatty acid and amino acid levels 
 
Metabolite 
Fasting 
(mmol/L)1 
Post-prandial 
(mmol/L)2 
Glucose 5 7 
Palmitate 0. 125 0.125 
Tetradecanoate 0.230 0.230 
Arginine 0.080 + 20 0.115 + 14 
Histidine 0.082 +10 0.118 +7 
Isoleucine 0.062 + 14 0.128 + 14 
Leucine 0.123 + 25 0.271 + 14 
Lysine 0.188 + 32 0.294 + 24 
Methionine 0.025 + 4 0.030 + 2 
Phenylalanine 0.057 + 9 0.068 + 4 
Threonine 0.140 + 33 0.182 + 13 
Tryptophan 0.044 + 7 0.036 + 3.6 
Valine 0.233 + 43 0.349 + 36 
Alanine 0.333 + 74 0.309 + 46 
Asparagine 0.041 + 10 0.045 + 2 
13 
 
 
Metabolite 
Fasting 
(mmol/L)1 
Post-prandial 
(mmol/L)2 
Aspartate 0.003 + 1 0.067 + 10 
Cysteine 0.052 + 11 0.093 + 10 
Glutamate 0.024 + 15 0.152 + 22 
Glutamine 0.586 + 84 0.541 + 25 
Glycine 0.230 + 52 0.281 + 33 
Proline 0.168 + 60 0.299 + 23 
Serine 0.114 + 19 0.175 + 11 
Tyrosine 0.059 + 12 0.092 + 9 
1. Cynober 2002  
2. Average of levels from Aoki et al., 1976; Tessari 
et al., 1996; and Pozefsky et al., 1969 
 
Supplementation was modeled by changing the available flux for each metabolite 
to an “unlimited” flux (99999 mmol/L/time).   For single amino acid 
supplementation, each amino acid was supplemented one at a time.  For multiple 
supplementations, all combinations of double, triple, quadruple… up to 7 amino 
acids were supplemented. (Computational time and resources dramatically 
increased after that, and the interest here is finding a minimum number of amino 
acids, rather than increasing all the amino acids.)  If the protein synthesis flux 
increased compared to the normal condition, then it’s assumed that the increase 
in availability of the amino acid increased protein synthesis flux.  
Using the model, I first determined the protein synthesis flux for the contractile 
proteins in each of the four muscle tissues (Type 1, Type 2a, Type 2x, and Type 
2b) under both fasting and post-prandial states.  I then optimized protein synthesis 
(contractile protein complex) in both control and supplement conditions, and I 
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compared the resulting fluxes after optimization.  Simulating supplementation was 
achieved by removing the constraint on the supplemented amino acid(s).  I then 
optimized protein synthesis through the contractile protein complex described.  
The method is outlined in Figure 1. 
 
Figure 1. Experimental Procedure for Amino Acid Supplementation.  This 
figure describes the work flow used for the experiment.  A flux balance model of 
374 reactions and 341 metabolites describing human muscle tissue was 
developed.  Flux constraints based on fasting (Cynober 2002) and fed (Cynober 
et al. 2002, Aoki et al. 1976, Pozefsky et al. 1969) levels of glucose, fatty acids, 
and amino acids in blood were added.  With the given constraint, the contractile 
protein flux was determined.  Supplementation was simulated by relaxing the 
constraint on amino acids singly and in all combinations from 2-7 amino acids. If 
the resultant flux was greater than the control flux, then the flux and conditions 
were recorded.  (The contractile protein schematic is from Spirito et al., 1997.) 
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Data Analysis 
To make sense of the data and which amino acids are actually an artifact of being 
important or just available in lower quantities, the number of amino acids that are 
needed were compared to the number that were available (Table 3).  The number 
of each amino acid that is needed is based on a count of the amino acids in each 
of the protein and subunits of the proteins which make up the protein complex unit 
(Table 1).  The amount that is available was determined by converting the amount 
available in mmol divided by the control protein flux: 2.18x10-5 mmol/time (Table 
4).  Next, the difference of what is needed from what is available was determined 
and the amino acids were ranked by difference (Expected Supplementation 
Effect).   The Actual Supplementation Effect is which amino acids were effective 
at increasing protein flux from single to 7 amino acid combinations (Table 3). 
Table 3. Amino Acids Needed Compared to the Amino Acids Available to produce 
one contractile protein complex in Type 2a.  Table 3A is the fasting state ranked 
by difference.  Table 3B is the fasting state ranked by essentiality (ce and e 
considered essential) and then by difference.  Table 3C is the post-prandial state 
ranked by difference. Table 3D is the post-prandial state ranked by essentiality (ce 
and e considered essential) and then by difference.  (Act Sup Eff—Actual 
Supplementation Effect; AA Ess—Amino Acid Essentiality; ce—conditionally 
essential; e – essential; ne – non-essential) 
 
Table 3A. Fasting state ranked by difference 
AA Needed Available Difference Rank Act Sup Eff AA Ess 
GLU 4996 1102 -3894 1 n/a ne 
ASP 2162 138 -2024 2 n/a ne 
MET 1148 1148 0 3 1 e 
ASN 1592 1883 291 4 n/a ne 
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AA Needed Available Difference Rank Act Sup Eff AA Ess 
ILE 2191 2847 656 5 2 e 
PHE 1363 2617 1254 6 5 e 
ARG 2133 3674 1541 7 4 ce 
LEU 3909 5648 1739 8 3 e 
TRP 227 2020 1793 9 n/a e 
TYR 798 2709 1911 10 n/a ne 
CYS 472 2388 1916 11 n/a ne 
HIS 735 3765 3030 12 n/a ce 
SER 2118 5235 3117 13 n/a ne 
THR 2174 6429 4255 14 7 e 
LYS 4132 8633 4501 15 6 e 
PRO 1308 7715 6407 16 n/a ne 
GLY 2165 10562 8397 17 n/a ne 
VAL 1938 10699 8761 18 n/a e 
ALA 3668 15291 11623 19 n/a ne 
GLN 2390 26909 24519 20 n/a ne 
 
Table 3B. Fasting state ranked by essentiality (ce and e are both considered 
essential) and then by difference 
AA Needed Available Difference Rank Act Sup Eff AA Ess 
MET 1148 1148 0 1 1 e 
ILE 2191 2847 656 2 2 e 
PHE 1363 2617 1254 3 5 e 
ARG 2133 3674 1541 4 4 ce 
LEU 3909 5648 1739 5 3 e 
TRP 227 2020 1793 6 n/a e 
HIS 735 3765 3030 7 n/a ce 
THR 2174 6429 4255 8 7 e 
LYS 4132 8633 4501 9 6 e 
VAL 1938 10699 8761 10 n/a e 
GLU 4996 1102 -3894 11 n/a ne 
ASP 2162 138 -2024 12 n/a ne 
ASN 1592 1883 291 13 n/a ne 
TYR 798 2709 1911 14 n/a ne 
CYS 472 2388 1916 15 n/a ne 
SER 2118 5235 3117 16 n/a ne 
PRO 1308 7715 6407 17 n/a ne 
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AA Needed Available Difference Rank Act Sup Eff AA Ess 
GLY 2165 10562 8397 18 n/a ne 
ALA 3668 15291 11623 19 n/a ne 
GLN 2390 26909 24519 20 n/a ne 
 
 
 
Table 3C. Post-prandial state ranked by difference 
AA Needed Available Difference Rank Act Sup Eff AA Ess 
GLU 4996 918 -4078 1 n/a ne 
ASP 2162 115 -2047 2 n/a ne 
MET 1148 957 -191 3 1 e 
ASN 1592 1569 -23 4 n/a ne 
ILE 2191 2373 182 5 4 e 
LEU 3909 4707 798 6 5 e 
PHE 1363 2181 818 7 2 e 
ARG 2133 3061 928 8 3 ce 
TRP 227 1684 1457 9 n/a e 
TYR 798 2258 1460 10 n/a ne 
CYS 472 1990 1518 11 n/a ne 
SER 2118 4362 2244 12 n/a ne 
HIS 735 3138 2403 13 n/a ce 
LYS 4132 7194 3062 14 6 e 
THR 2174 5357 3183 15 7 e 
PRO 1308 6429 5121 16 n/a ne 
GLY 2165 8801 6636 17 n/a ne 
VAL 1938 8916 6978 18 n/a e 
ALA 3668 12743 9075 19 n/a ne 
GLN 2390 22425 20035 20 n/a ne 
 
Table 3D. Post-prandial state ranked by essentiality (ce and e considered 
essential) and then by difference 
AA Needed Available Difference Rank Act Sup Eff AA Ess 
MET 1148 957 -191 1 1 e 
ILE 2191 2373 182 2 4 e 
LEU 3909 4707 798 3 5 e 
PHE 1363 2181 818 4 2 e 
ARG 2133 3061 928 5 3 ce 
TRP 227 1684 1457 6 n/a e 
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AA Needed Available Difference Rank Act Sup Eff AA Ess 
HIS 735 3138 2403 7 n/a ce 
LYS 4132 7194 3062 8 6 e 
THR 2174 5357 3183 9 7 e 
VAL 1938 8916 6978 10 n/a e 
GLU 4996 918 -4078 11 n/a ne 
ASP 2162 115 -2047 12 n/a ne 
ASN 1592 1569 -23 13 n/a ne 
TYR 798 2258 1460 14 n/a ne 
CYS 472 1990 1518 15 n/a ne 
SER 2118 4362 2244 16 n/a ne 
PRO 1308 6429 5121 17 n/a ne 
GLY 2165 8801 6636 18 n/a ne 
ALA 3668 12743 9075 19 n/a ne 
GLN 2390 22425 20035 20 n/a ne 
 
 
Results 
Single Amino Acid Supplementation 
The purpose of this study is to determine if constraint based modeling is an 
effective tool for investigating nutrition supplementation.  To achieve this, I ask a 
specific question: can increasing single or multiple amino acid uptake flux lead to 
increased muscle synthesis of the contractile protein complexes (see methods) 
assuming the muscle tissue is primed for protein synthesis (post-exercise stimulus) 
without including genetic and regulatory controls (an acute response).  The first 
step was to investigate single acid supplementation, and after optimizing the model 
for contractile protein synthesis under fasting and post-prandial conditions, I 
relaxed each amino acid constraint one at a time.  For single amino acid 
supplementation in both fasting and post-prandial states, methionine was the only 
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amino acid effective at increasing the protein flux above the control condition 
(Table 4).  .   
Multiple Amino Acid Supplementation 
Quite often supplementation regimes occur in combinations with many 
supplements/amino acids.  The next step was to determine if the model predicted 
that specific combinations of supplements result in increased protein synthesis.  I 
then relaxed the constraints for every combination of 2-7 amino acids to determine 
what combinations would increase contractile protein synthesis above the control 
fasting and post-prandial states.  Once I supplemented with methionine the 
combination in the fasting and post-prandial states vary slightly.  For instance, the 
combination of three amino acids in the fasting state differs than the optimal 
combination in the post-prandial state (Table 4).  In fasting, methionine, isoleucine, 
and leucine were most optimal at increasing protein synthesis, yet in the post-
prandial state, the optimal combination of amino acids is methionine, arginine, and 
phenylalanine, due to differing amino acid concentrations in the two different 
nutrient states.   
However, when investigating the optimal condition for five supplements, the results 
in both the fasting and post-prandial states were the same: methionine, arginine, 
isoleucine, leucine, and phenylalanine (Table 4).  In six and seven combinations, 
the addition of lysine and threonine increased protein synthesis, respectively 
(Table 4). 
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Table 4. Type 2a contractile protein flux synthesis in fasting and post-prandial 
states for every combination of 1 -7 amino acids. Post-abs: post-prandial 
Combination 
Supplement: 
Fasting 
Fasting: 
(10-05 mmol/L/time*) 
Supplement: 
Post-abs 
Post-prandial  
(10-05 mmol/L/time*) 
n/a Control 2.18 Control 2.61 
1 Methionine 2.83 Methionine 4.99 
2 
Methionine, 
Isoleucine 
3.15 
Methionine, 
Phenylalanine 
5.39 
3 
Methionine, 
Isoleucine, 
Leucine 
3.75 
Methionine, 
Phenylalanine, 
Arginine 
5.84 
4 
Methionine, 
Isoleucine, 
Leucine, 
Arginine 
4.18 
Methionine, 
Phenylalanine, 
Arginine, 
Isoleucine 
6.93 
5 
Methionine, 
Isoleucine, 
Leucine, 
Arginine,  
Phenylalanine 
4.55 
Methionine, 
Phenylalanine, 
Arginine, 
Isoleucine, 
Leucine 
7.12 
6 
Methionine, 
Isoleucine, 
Leucine, 
Arginine,  
Phenylalanine, 
Lysine 
6.44 
Methionine, 
Phenylalanine, 
Arginine, 
Isoleucine, 
Leucine, Lysine 
8.37 
7 
Methionine, 
Isoleucine, 
Leucine, 
Arginine,  
Phenylalanine, 
Lysine, 
Threonine 
10.6 
Methionine, 
Phenylalanine, 
Arginine, 
Isoleucine, 
Leucine, Lysine, 
Threonine 
13.0 
*time is not defined. 
 
Discussion 
I focused on Type 2A muscle tissue because it responds to exercise by increasing 
the contractile proteins, while other tissue types respond to exercise through other 
means (like increasing mitochondrial content).  The significance of these results is 
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apparent when comparing the amount of amino acids needed to build one 
contractile protein complex to what is available (Table 3).  One would expect that 
methionine and isoleucine, respectively, should be the top two amino acids needed 
to increase protein flux because these essential amino acids have the largest 
differences between what is available and what is needed (Table 3B).  As 
expected, this is also what the model shows.  However, it is interesting the model 
then predicts that leucine and valine are the next important essential amino acids 
necessary at increasing the protein flux even though, based on availability 
differences, one would expect phenylalanine and tryptophan would be the next 
effective supplements (Table 3B).  Arginine, a conditionally essential amino acid 
is also greater than expected in supplementation affect based on essentiality and 
availability differences (Table 3B).  Results are similar when investigating the data 
in post-prandial state.  According to the rank between what is available and what 
is needed, methionine, isoleucine, and leucine should be the most effective, but in 
fact the model shows that phenylalanine and arginine are more effective. 
The advantage of using this metabolic modeling is being able to track the fluxes 
for each of the metabolites.  Thus, one can predict why the results differ than what 
is expected if availability is the only factor.  Not only is there an increase in 
contractile protein synthesis when relaxing the constraint on methionine, the model 
predicts that there is a change in how energy is produced in support for protein 
synthesis (Figure 2B).  As seen in Figure 2B, there is a decrease in glycolysis 
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from glucose and a decrease in fatty acid oxidation from palmitate.  Some of the 
energy for the synthesis process comes from increased lysine oxidation among 
changes in other amino acid catabolism, such as asparagine, serine, and glycine.  
Glutamine is predicted to be made in excess and transported out of the muscle 
tissue.  This process increases the TCA cycle and the NADH shuttle to the 
mitochondria (facilitated by the malate and alpha-ketoglutarate exchange seen in 
Figure 2B).  
Although relaxing the constraints on the other single amino acid supplementation 
conditions did not increase contractile protein synthesis, it did alter the metabolic 
profile of the network compared to the control condition.  Here I will describe a few 
of the different profiles based on different supplementation conditions.  For 
example, the model predicts the usage of the BCAAs as a preferred energy source, 
even in single amino acid supplementation (Figures 2D and 2E).  Thus, it is 
predicted that all the available BCAAs (isoleucine, leucine, and valine) will be 
absorbed and used, whether as a building block for proteins or an energy source 
for ATP production. Increasing the available BCAAs increases the flux through the 
branched-chain amino acid transaminase enzyme (BCAT-2).  Increased flux 
through BCAT-2 increases the byproduct of glutamate.  The increased BCAT-2 
flux requires an increase in the fluxes through the malate-aspartate shuttles and 
ultimately leads to an increase in serine production.  This process reduces the 
need of serine, and as such, less serine is taken into the cell compared to no BCAA 
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supplementation.  In summary, the model shows that if the availability of BCAAs is 
increased, then the muscle tissue doesn’t require as much serine to build 
contractile proteins (Figures 2D and 2E).  This is also a similar process for 
supplementation of alanine, aspartate, glutamate, and proline.  Under these 
conditions less serine is required to achieve the same result in protein synthesis 
flux.  Also, when extra glutamine is supplied to the model, less asparagine is 
needed.   
A. Pathway Assignment 
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B. Methionine Supplementation 
 
 
C. Isoleucine Supplementation 
 
  
 
 
 
 
25 
 
 
 
 
 
 
D. Leucine Supplementation 
 
 
E. 3 AA Supplementation 
  
 
  
Figure 2. Flux differences compared to control show how increased amino 
acids could be used. This figure shows the changes in fluxes from the control 
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solution described in methods.  (A) Manually assigned color key for pathways in 
the model.  (B) Shows the differences in fluxes between methionine supplementing 
and control.  (C) Shows the differences in fluxes between isoleucine 
supplementing and control.  (D) Shows the differences in fluxes between leucine 
supplementing and control. (E) Shows the differences in fluxes between the three 
amino acid supplementation (methionine, isoleucine, and leucine (Table 4) and 
control results  
 
Comparison to Literature – BCAA 
The model’s predictions are more similar to what is found in literature than what is 
expected based on availability differences.  BCAAs have been found to greatly 
increase protein synthesis.  Even though BCAA catabolism increases after 
exercise (Spirito et al., 1997), a popular current hypothesis is that they have a 
signaling effect and increase enzymes necessary for protein synthesis through 
activation of mTOR (Blomstrand et al., 2006; Spirito et al., 1997).  The model used 
here is void of any genetic controls, yet it still shows that increasing the 
bioavailability of these amino acids is enough to predict an increase in protein 
synthesis flux (Table 4).  The model predicts that the BCAAs are preferentially 
oxidized over glucose and fatty acids and used as an energy source rather than 
as a building block for the contractile proteins (Figure 2B).  It is possible that in 
addition to a signaling effect, BCAAs are effective at increasing protein synthesis 
by adding a more efficient acute energy source when energy is needed quickly for 
protein synthesis. 
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Comparison to Literature – Arginine 
Another pertinent revelation from the model is an amino acid combination where 
arginine is required to increase protein synthesis (Table 4, row 4 Fasting, row 3 
post-prandial).  In the literature, arginine supplementation had equivocal results.  It 
was hypothesized that arginine is only effective under certain amino acid profiles 
(Paddonn-Jones et al., 2004), but the exact profile is unknown.  As summarized in 
Table 4, row 4 in the fasting condition, the model shows that arginine is effective 
when supplemented with methionine, isoleucine, and leucine in the fasting state 
and effective in the post-prandial state when combined with methionine and 
phenylalanine (Table 4).  Most of the studies with arginine have been compared 
to either all the essential amino acids or none.  The model predicts two different 
scenarios where arginine is effective at increasing protein synthesis and could 
explain the mixed results seen in the literature. This could indicate that during 
fasting conditions, in between meals, or other times throughout the day different 
supplementation strategies could be important compared to supplementation with 
meals. 
Comparison to Literature – Glutamine 
Lastly, contrary to nutrition/supplement companies but consistent with the 
literature (Gleeson, 2008), glutamine supplementation is not predicted by the 
model to have an effect on protein synthesis.  It is the most abundant amino acid 
found in fasting blood at concentrations above what is needed for protein synthesis 
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of the contractile complexes (Table 3).  Glutamine is a byproduct of many reactions 
and easily synthesized in the body.  The model also shows glutamine is not found 
in the top seven amino acids which show an increase in protein synthesis (Table 
4). In fact, the model predicts an abundance of glutamine is made and eliminated 
from muscle tissue in some conditions (data not shown).  
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Metabolic Modeling of Muscle Metabolism Identifies Key 
Reactions Linked to Insulin Resistance Phenotypes2 
Introduction 
Type 2 diabetes (T2D) has reached epidemic proportions worldwide, in parallel 
with the dramatic increase in obesity (Centers for Disease Control and Prevention, 
2011).  Insulin resistance plays a particularly important role in T2D 
pathophysiology, as it is present years before the onset of hyperglycemia and can 
predict the subsequent development of diabetes decades later (Martin et al., 1992; 
Tabak et al., 2009).  Although insulin resistance occurs in multiple tissues, skeletal 
muscle is a key tissue, being responsible for over 80% of insulin-stimulated 
glucose uptake (DeFronzo et al., 1985).   
While the molecular basis of insulin resistance remains unknown, insulin 
resistance in skeletal muscle is intimately linked to alterations in metabolism.  
These include (1) reductions in glucose uptake, non-oxidative glucose metabolism, 
and glycogen synthesis (Eriksson et al., 1989; Vaag et al., 1992); (2) reduced lipid 
oxidation (Kelley and Simoneau, 1994; Boyle et al., 2012) and accumulation of 
                                            
 
2 This chapter is based on material from a forthcoming publication, “Muscle Metabolic Modeling of 
Insulin Resistance” by Christopher D. Nogiec, Alison Burkart, Carles Lerin, Simon Kasif, and Mary-
Elizabeth Patti.  Alison Burkart performed the in vitro studies and corresponding data analysis. All 
authors have agreed to have the material included in this dissertation. 
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multiple lipid species (Jacob et al., 1999; Malenfant et al., 2001); (3) reduced TCA 
cycle activity (Befroy et al., 2007; Simoneau and Kelley, 1997); and (4) increased 
reactive oxygen species (ROS) (Anderson et al., 2009).  Moreover, in vivo NMR 
spectroscopy in insulin resistant humans has demonstrated abnormal energetics, 
including reductions in ATP and creatine phosphate (Cr-P) synthesis at rest 
(Petersen et al., 2004) and in response to insulin (Petersen et al., 2005) and 
exercise training (Kacerovsky-Bielesz et al., 2009).  Transcriptome analysis has 
similarly demonstrated dysregulation of mitochondrial regulatory genes in insulin 
resistance and established T2D (Patti et al., 2003; Mootha et al., 2003; Boyle et 
al., 2011). While these data highlight the close relationship between disordered 
metabolism and insulin resistance, it remains unknown which alterations in 
metabolic reactions might cause the changes in metabolic phenotypes associated 
with or contributing to insulin resistance.   
Given the complexity and redundancy of metabolism, it is difficult to address this 
question experimentally. To approach this challenge, I used a constraint-based 
modeling framework and FBA muscle model.  Specifically, I incorporate reciprocal 
modulation of lipid oxidation and glucose uptake in order to model the fasted-to-
fed transition, under conditions of both normal and increased substrate availability. 
Using this model, I then systematically perturb the metabolic network by 
performing in silico knockdowns of each of the 388 reactions within the model and 
identify those perturbations which produce metabolic phenotypes associated with 
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IR: (1) reduced ATP+Cr-P synthesis, (2) reduced cumulative TCA cycle flux, and 
(3) reduced metabolic flexibility.  The analysis suggests that single-enzyme 
knockdowns do not reproduce these phenotypes. However, knockdowns in the 
pyruvate dehydrogenase flux in combination with either reduced fatty acid uptake 
or fatty acid/amino acid oxidative metabolism (electron-transferring-flavoprotein 
dehydrogenase) reduces ATP+Cr-P synthesis, reduces cumulative TCA cycle flux, 
and induces metabolic inflexibility.  These combined knockdowns also reduce 
glycogen storage and lipid oxidation and increase incomplete lipid oxidation, other 
phenotypes associated with IR.  Thus, this computational model serves as a novel 
tool to identify candidate enzymes linked to the pathogenesis of dysregulated 
metabolism in IR. 
 
Methods 
Choosing the Objective Function 
I made the assumption that the main objectives of resting muscle tissue (either 
during the fasting state or fed state) is to maximize a complex objective function 
combining storage of energy in the forms of high-energy phosphates (ATP+ Cr-P), 
glycogen, and TAG for energy needs during subsequent contraction.  Given the 
importance of ATP+Cr-P as an acute energy source in muscle, I weighted the sum 
of ATP+Cr-P production to be twice that of the other energy storage molecules.  
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For ATP production, I maximize a reaction within the model describing ATP 
storage (Eq. 1), encompassing both aerobic and non-aerobic ATP production. 
 
Eq.1:  
 𝐴𝑇𝑃 𝑠𝑡𝑜𝑟𝑎𝑔𝑒 =  ∑(𝑎𝑒𝑟𝑜𝑏𝑖𝑐 𝐴𝑇𝑃 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛)  +  ∑(𝑛𝑜𝑛𝑎𝑒𝑟𝑜𝑏𝑖𝑐 𝐴𝑇𝑃 𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛)   
 
 
For Cr-P, glycogen, and TAG, I maximize flux through reactions describing storage 
for each substrate.  Since muscle tissue can only store a finite amount of ATP+Cr-
P, I set an upper limit of 33.3 and 116.7 mmol/time for ATP+Cr-P production, 
respectively, based on prior data demonstrating an approximate 3.5-fold ratio of 
Cr-P to ATP content (Sleigh et al., 2011; Gray et al., 2008).  This allows extra 
substrate to be stored optimally in glycogen, triacylglycerols, or muscle protein. 
Modeling the Dynamics of Normal Metabolism 
Flux balance analysis (FBA) typically models metabolism in a steady state, but to 
properly model the conditions associated with a disease state, it was necessary to 
simulate the metabolic transitions between fasting and fed conditions.  To this aim, 
I reciprocally modulate lipid oxidation and glucose uptake.  Given that lipid 
substrate utilization is maximal in the fasting state and reduced in the fed state, I 
first modulated lipid oxidation by limiting CPT1—the enzyme controlling fatty acid 
transfer into mitochondria for subsequent oxidation—from a maximum activity of 
100% (fasted) to a minimum of 0% (fed) through a progressive stepwise reduction 
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in activity (Figure 3).  I simultaneously modeled glucose uptake in two distinct 
components:  basal and modifiable.  First, I estimated basal glucose uptake 
(GUbas) to be 5% of the glucose concentration in plasma, constant across the 
fasted to fed transition (Kraegen et al., 1993; Kelley et al., 1993; Kelley et al., 1992; 
Mandarino et al., 1993).  In addition to the constant GUbas, I modeled a modifiable 
glucose uptake (GUmod), specified by adjusting the maximal glucose uptake from 
0% to 100% of the concentration found in plasma (Figure 3).  I defined three 
steady states across this continuum: fasted (90% CPT1, 10% GUmod), mixed 
(50% CPT1, 50% GUmod), and fed (10% CPT1, 90% GUmod) (Figure 3).  These 
steady states were used to examine the impact of the metabolic condition on in 
silico KDs (see In Silico Knockdowns below). In all conditions, I allow free uptake 
of fatty acids and amino acids up to the values found in plasma in healthy fasting 
individuals (Jin et al., 2011; Cynober, 2002).  
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Figure 3.  Simulating fasting to fed transition by reducing CPT1 activity and 
increasing a modifiable glucose uptake component.  To simulate the fasting-
to-fed transition, and associated shifts from fatty acid to glucose metabolism, I 
experimentally modulated flux through carnitine palmitoyl-transferase 1 (CPT1) 
and a modifiable component of glucose uptake (GUmod).   Flux is sampled at 
discrete percentages of maximal flux through CPT1 and GUmod.  I define fasted 
(90% CPT1: 10% GUmod), mixed (50% CPT1: 50% GUmod), and fed states (10% 
CPT1: 90% GUmod). 
 
 
Nutrient Conditions 
Since prevailing nutrient conditions are a key determinant of cellular metabolism, I 
assigned basal (1x) concentrations of extracellular glucose, fatty acids, and amino 
acids as extrapolated from measurements obtained from healthy subjects (Jin et 
al., 2011; Cynober, 2002) (Table 5).  To examine the impact of increased substrate 
availability, as seen in patients with insulin resistance and T2D, I also created three 
additional nutrient conditions, yielding increased fatty acids and glucose 
independently (2xFA-1xGluc or 1xFA-2xGluc) and in combination (2XFA-2XGluc).    
Table 5. Basal concentrations used as 
maximal uptake fluxes in the Flux Balance 
Model. 
Metabolite Concentration (mmol/L)1 
Glucose¥ 5.00 
Palmitate¥ 0. 3875 
Arginine 0.080 + 20 
Histidine 0.082 + 10 
Isoleucine 0.062 + 14 
Leucine 0.123 + 25 
Lysine 0.188 + 32 
Methionine 0.025 + 04 
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Phenylalanine 0.057 + 09 
Threonine 0.140 + 33 
Tryptophan 0.044 + 07 
Valine 0.233 + 43 
Alanine 0.333 + 74 
Asparagine 0.041 + 10 
Aspartate 0.003 + 01 
Cysteine 0.052 + 11 
Glutamate 0.024 + 15 
Glutamine 0.586 + 84 
Glycine 0.230 + 52 
Proline 0.168 + 60 
Serine 0.114 + 19 
Tyrosine 0.590 + 12 
 
1. Cynober et al. (2002), Jin et al. (2011) and 
MacLaren (2000),  
¥Glucose and Fatty Acid are based on internal 
data collected in the Patti Lab 
 
In Silico Knockdowns 
I simulated knockdowns (KDs) of each reaction R by constraining the flux for R to 
50% its normal, optimal value. This was done for each of the three defined states 
(fasted, mixed, and fed) resulting in possibly three different KD flux values—one 
for each of the states, respectively. After constraining the reaction to this new, 
reduced value, I re-optimized the model to obtain another set of fluxes (Figure 4) 
and compared metabolic phenotypes to the basal (no knockdown) condition.   
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Figure 4.  Work flow for the in silico knockdown experiments.  
In the first step, I select the nutrient state.  Next, I then select the model state: 
fasted (90% CPT1:10% GUmod), mixed (50% CPT1:50% GUmod), or fed (10% 
CPT1:90% GUmod).  In the third step, the model produces a normal set of optimized 
fluxes for each reaction.  In the fourth step, I define the KD flux for a single reaction 
(50% of normal flux) and set that as an additional constraint to the model.  Fifth, I 
again optimize to obtain a new set of fluxes reflecting the KD.  Then, I repeat steps 
4 and 5 for each of the 388 reactions in the model (Nogiec Muscle Model v1.1). 
 
 
Modeling Insulin Resistance Phenotypes 
The goal is to identify metabolic reaction(s) or network(s) whose dysregulation may 
perturb muscle metabolism sufficiently to yield metabolic phenotypes observed in 
IR.  Given that this model does not incorporate insulin signaling networks, three 
key metabolic phenotypes characteristic of human insulin resistance are used as 
a proxy for insulin resistance: (1) reduced ATP+Cr-P  production (Petersen et al., 
2004; Petersen et al., 2005), (2) reduced flux through TCA cycle (Befroy et al., 
2007; Simoneau and Kelley, 1997),  and (3) reduced metabolic flexibility (Kelley 
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and Mandarino, 2000).  In order to determine the effect of in silico KDs on these 
phenotypes, I define them mathematically for the model.  For ATP production, I 
monitor a reaction within the model describing ATP storage (Eq. 1), encompassing 
both aerobic and non-aerobic ATP production.  For Cr-P, I examine the creatine 
kinase reaction (Eq. 2).  To quantify TCA cycle activity, I sum the fluxes through 
all reactions within the TCA cycle (Eq. 3).   
 
Eq. 2: 
𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑒 + 𝐴𝑇𝑃 =  𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑒 𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 + 𝐴𝐷𝑃 
 
Eq. 3: 
∑(𝑇𝐶𝐴 𝐹𝑙𝑢𝑥) =  𝑐𝑖𝑡𝑟𝑎𝑡𝑒 𝑠𝑦𝑛𝑡ℎ𝑎𝑠𝑒 +  𝑎𝑐𝑜𝑛𝑖𝑡𝑎𝑠𝑒 +  𝑖𝑠𝑜𝑐𝑖𝑡𝑟𝑎𝑡𝑒 𝑑𝑒ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑛𝑎𝑠𝑒 2 
+    𝛼 𝑘𝑒𝑡𝑜𝑔𝑙𝑢𝑡𝑎𝑟𝑎𝑡𝑒 𝑑𝑒ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑛𝑎𝑠𝑒 
+  𝑠𝑢𝑐𝑐𝑖𝑛𝑦𝑙 𝐶𝑜𝑒𝑛𝑧𝑦𝑚𝑒𝐴 𝑠𝑦𝑛𝑡ℎ𝑒𝑡𝑎𝑠𝑒 
+  𝑠𝑢𝑐𝑐𝑖𝑛𝑎𝑡𝑒 𝑑𝑒ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑛𝑎𝑠𝑒 (𝐶𝑜𝑚𝑝𝑙𝑒𝑥 𝐼𝐼) +  𝑓𝑢𝑚𝑎𝑟𝑎𝑠𝑒 
+   𝑚𝑎𝑙𝑎𝑡𝑒 𝑑𝑒ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑛𝑎𝑠𝑒 2 
Metabolic flexibility, defined as the ability to modulate between fatty acid and 
glucose oxidation in response to feeding or insulin stimulation (Kelley and 
Mandarino, 2000), is quantified in clinical research by examining changes in the 
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respiratory quotient (RQ), which reflects the ratio of carbon dioxide produced 
relative to the oxygen consumed (Eq. 4).   
Eq. 4: 
𝑅𝑄 =
𝐶𝑂2 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛
𝑂2 𝑐𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛
 
 
To determine whether experimental disruption in flux for a metabolic reaction 
causes changes in these characteristic metabolic phenotypes, I compared 
phenotypic scores from each KD to the corresponding phenotypic score from the 
normal (control) score.  Since ATP and Cr-P production are closely linked in 
muscle, I summed these high-energy phosphate molecules to simplify the analysis 
(ATP+Cr-P).  Thus, I assessed the ratio of KD to control for the ATP+Cr-P-
production and cumulative-TCA-flux phenotypes (Eq. 5 and 6): 
Eq. 5:  
ATP+Cr-P ratio   =
𝛴 (𝐾𝐷 𝐴𝑇𝑃+𝐶𝑟−𝑃 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛)
𝛴 (𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴𝑇𝑃+𝐶𝑟−𝑝 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛)
  
 
Eq. 6:  
 𝑇𝐶𝐴 𝑟𝑎𝑡𝑖𝑜 =
∑  𝐾𝐷 𝑇𝐶𝐴 𝑓𝑙𝑢𝑥
∑𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑇𝐶𝐴 𝐹𝑙𝑢𝑥
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In normal metabolism, RQ (Eq. 4) increases as the individual shifts from fatty acid 
oxidation in the fasting state to glucose oxidation in the fed state (Kelley and 
Mandarino, 2000).  In contrast to healthy, insulin sensitive individuals, insulin 
resistant and obese individuals have (1) higher fasting RQs AND (2) lower fed 
RQs.  Since both of the above phenotypes need to be true to indicate metabolic 
inflexibility, I thus define it as a logical, binary equation (Eq. 7): 
Eq. 7:   
metabolic inflexibility = (KD RQfast > Control RQfast) AND (KD RQfed < Control RQfed)  
If Eq. 7 is true, I then assess the magnitude of difference between fasted and fed 
RQ values: a greater difference indicates more decreased flexibility/increased 
inflexibility (Eq. 8).    
 Eq. 8: 
Metabolic inflexibility score = IF (metabolic inflexibility = TRUE),  
then (|KD RQfast – Control RQfast| + (KD RQfed – Control 
RQfed|) 
else 0 
Ratios less than one for either ATP+Cr-P production (Eq. 5) or cumulative TCA 
flux (Eq. 6) and any non-zero score for metabolic flexibility (Eq. 8.) are considered 
to reflect IR phenotypes.  Significance of each score was determined by comparing 
the score to the distribution of the scores for each phenotype. 
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Pathway Analysis 
I assigned each of the 388 model reactions to a KEGG pathway(s) based on its 
EC number, or if none were available, I assigned one manually (Appendix A).  I 
also created pathways including reactions utilizing common energy substrates 
(e.g. creatine, nicotinamide adenine dinucleotide (NAD(H)), and flavin adenine 
dinucleotide (FAD(H))) and defined a cytosolic-mitochondrial NADH shuttle 
pathway. Finally, an “All Reactions Pathway,” containing all 388 reactions in the 
model, was used as the background distribution.  I then used the Fisher’s exact 
test to determine if any of the pathways was significantly enriched in modulating 
the three metabolic phenotypes in any of the 3 defined states (fasted, mixed, fed) 
or four nutrient conditions—i.e., whether the number of perturbations in a specific 
pathway that alter the phenotype is greater than expected by chance.  To account 
for multiple-hypothesis testing, I used the Benjamini-Hochberg method to calculate 
false discovery rate (FDR).  
Modeling Assumptions 
In addition to assumptions made with the FBA model (Oberhardt et al., 2009), I 
add three additional assumptions.  First, this modeling approach assumes that 
necessary hormones and enzymes are in place to seamlessly modulate fuel 
metabolism between fatty acid and glucose metabolism.  Secondly, because the 
flux into muscle of all lipid and amino acid species is unknown, I assume the uptake 
flux is proportional to plasma concentrations (Cynober, 2002; MacLaren et al., 
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2000).  Finally, I assume the system reaches a steady state over enough time to 
maintain constant flux, and that concentrations of substrates in plasma will be 
stably maintained over time. 
RT-PCR of S961 IR Mouse Model3 
Mice were treated with S961 at 10 nMol/week to induce insulin resistance (Yi et 
al., 2013).  Total RNA was extracted from gastrocnemius muscle by using RiboZol 
reagent (AMRESCO, Solon, OH, USA). For quantitative mRNA analysis, 1 µg of 
total RNA was reverse-transcribed with High Capacity cDNA Reverse 
Transcription Kit (Life Technologies, Carlsbad, CA, USA). The cDNA reaction was 
subjected to quantitative real-time PCR analysis using iTaq Universal SYBR Green 
Supermix (Bio-Rad, Hercules, CA, USA) and ABI 7900HT Real-Time PCR System 
(Life Technologies), following the manufacturer’s instructions. Tbp was used as an 
internal housekeeping gene. Relative gene expression was calculated by the 2-
ΔΔCT method. 
Primary Cell Preparation and Transfection4 
All leg muscles were isolated from 4-week-old PDK2/4 KO mice (Jeoung and 
Harris, 2007) and wild type control mice by digesting with 2.4 U/mL dispase and 
                                            
 
3 Ana-Luisa Coelho, PhD, performed these methods. 
4 Alison Burkart, PhD, performed these methods. 
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1% collagenase. Cells were grown in F10 medium supplemented with 20% fetal 
bovine serum and penicillin/streptomycin. Myoblasts were selected for by 
differential plating upon successive passages until cultures were over 97% pure. 
We used specific siRNA oligonucleotides against ETFDH or a scrambled control 
that were transfected by HiPerFect, based on manufacturer’s instructions.   
Western Blot Analysis5 
At 72 hours post KD, total protein was obtained by lysis with 1% sodium dodecyl sulfate 
in phosphate-buffered saline (PBS). Protein concentrations were determined with a 
bicinchoninic acid assay (BCA; Pierce – ThermoScientific Fisher, Rockford, IL, USA). 
Equal amounts of protein were run on a 10% SDS-PAGE gel and transferred to 
nitrocellulose. Membranes were blocked in 5% milk for one hour and then incubated with 
primary antibodies as indicated. Specific secondary antibodies and enhanced 
chemiluminescence reagents were used to visualize bands. 
Respiration Studies5 
Cellular respiration was assessed using a Seahorse XF24 Flux Analyzer. Cells 
were treated overnight with 250 uM palmitate in BSA. The following day, cells were 
washed twice in PBS, then put in KRB buffer with 5.5 mM glucose and 250 uM 
palmitate in BSA for 1 hr. Basal oxygen consumption rate (OCR) and extracellular 
                                            
 
5 Alison Burkart, PhD, carried out these methods. 
43 
 
 
acidification rate (ECAR) were measured 4 times over a period of 20 mins. Then, 
5.5 mM glucose was injected into each well and the OCR and ECAR were 
measured 4 times over 20 mins. After the assay, media was aspirated and DNA 
was isolated for normalization. 
Citrate Synthase Activity Assay6 
Citrate synthase (CS) activity was determined using an enzymatic method based 
on a commercially available assay kit (CS0720 Sigma, St. Louis, MO, USA). Cells 
were lysed in RIPA buffer and added to a 96 well plate. Assay buffer (100 mM Tris 
pH 7.5) with 300 nM Acetyl-CoA and 100 nM DTNB (5,5'-dithiobis-(2-nitrobenzoic 
acid) was added to all wells. Plate was read at 412 nm for 1.5 mins, with a read 
every 10 seconds to determine endogenous CS activity. The curve slope was used 
to calculate the enzymatic activity, a BCA assay was used to normalize the data 
per milligram of protein. 
Adenosine Nucleotide Measurements7 
Levels of adenine nucleotides were measured by a coupled enzymatic assay 
(Detimary et al., 1995).  Cells were grown in an opaque 96-well plate with clear 
bottom. Cells were washed twice in PBS, then put in KRB buffer with 5.5 mM 
                                            
 
6 Alison Burkart, PhD, carried out these methods. 
7 Alison Burkart, PhD, carried out these methods. 
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glucose for 1 hr. Next, 100 ul of the CellTiter-Glo luminescent assay reagent 
(Promega, Fitchburg, WI, USA) was added and incubated for 15 min. 
Luminescence was read using a multiplate reader. Untreated wells were used to 
determine relative protein content by BCA assay to normalize the data. 
. 
Results 
Model Development and Validation   
As described more fully in Methods, I have developed a model of muscle 
metabolism incorporating 388 distinct reactions. I use the technique of flux balance 
analysis (FBA), which optimizes flux through a set of reactions (in this case, the 
metabolic network of muscle tissue) to achieve a specific objective function. Given 
that muscle metabolism at rest is focused on energy storage in preparation for 
subsequent physical activity, I assigned the objective function as storage of ATP, 
creatine phosphate (Cr-P), glycogen, and triacylglycerols (TAG).  I limited maximal 
ATP and Cr-P to 33.3 and 116.7 mmol/L/time, respectively, to achieve a dynamic 
range during the fasting to fed transition and to allow for storage of excess energy 
in the fed state.  This ratio of 3.5 Cr-P to 1 ATP was chosen on the basis of prior 
metabolite assays in muscle (Sleigh et al., 2011; Sleigh et al., 2012; Gray et al., 
2008).  I did not constrain glycogen nor TAG, given their wide variation in distinct 
nutrient conditions and training states (Sacchetti et al., 2004).  While FBA typically 
models steady-state metabolism, I simulated dynamic shifts across the fasting-fed 
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transition by modulating mitochondrial fatty acid uptake and cellular glucose 
uptake.  Specifically, I constrained activity of CPT1 (the rate-limiting step of 
mitochondrial fatty acid update), assigning maximal activity in fasting state with 
progressive stepwise reductions toward the fed spectrum (Figure 3).  For glucose 
uptake, I similarly assigned both a constant basal component and a modifiable 
component which increased progressively from fasted to fed states (Figure 3).   In 
each state, the model allows free uptake of fatty acids and amino acids up to the 
concentrations found in fasting human plasma (Cynober, 2002; MacLaren et al., 
2000), as needed to meet the energetic objective functions. 
I next examined flux through key reactions at each step in the fasted-fed spectrum 
to confirm that this model mirrored expected metabolic profiles in normal human 
subjects.  ATP+Cr-P production reach maximal levels in the fed state, with excess 
energy stored as glycogen and triacylglycerols (Figure 5A).  Similarly, TCA cycle 
cumulative flux increases in the fed state (Figure 5B).  As expected, glycolytic flux 
increases in the fed state, concurrent with increased glucose availability, while 
substrate exchange (including amino acid uptake) and amino acid oxidation remain 
constant.  Consistent with the net increase in glucose oxidation and reduction in 
fatty acid oxidation in the fasted to fed transition, respiratory quotient (RQ) 
increased in the fed state (Figure 5C).  Changes in flux through all the reactions 
are represented in the model across the fasted-to-fed transition are visualized in 
Figure 6.  This analysis demonstrates the metabolic model faithfully recapitulates 
46 
 
 
the basic transitions in human metabolism in fasted and fed states allowing one to 
compare these states to hypothetical disease conditions. 
A.
 
B. 
 
C.
 
Figure 5.  Modeling muscle metabolism under normal nutrient conditions.  
(A) Fluxes for ATP+Cr-P, glycogen storage, and TAG storage.  (B) Cumulative 
TCA flux increases across the fasted to fed spectrum.  (c) Respiratory quotient 
(RQ) increases across the fasted to fed spectrum, as predicted from in vivo 
analysis.  . 
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Impact of Nutrient Availability   
Since the obesity/diabetes metabolic environment is characterized by increases in 
plasma levels of nutrient substrates, which may themselves contribute to altered 
flux, I tested the impact of increasing extracellular glucose and fatty acid availability 
by 2-fold over the fasting level (2X Gluc and 2X FA, respectively), both 
independently and in combination.  With increased glucose availability (2x Gluc), 
there is a leftward shift in glucose-dependent fluxes, occurring earlier in the fasted-
to-fed transition (Table 1 and Figure 6, panel B vs. panel A), including increased 
flux through glycolysis, glycogen storage, and TAG storage.  There was no major 
effect of 2X Gluc on substrate uptake, fatty acid/amino acid metabolism, TCA or 
OXPHOS, or creatine metabolism fluxes. 
Increased fatty acid availability (2X FA) (Table 6 and Figure 6C) increased flux 
through TCA, OXPHOS, glycogen storage, and TAG storage.  In each case, fluxes 
through these reactions occurred earlier in the fasted-to-fed transition, potentially 
consistent with increased energy availability in this state.  Increased availability of 
FA without an increase in energy demand (as dictated by model constraints on 
maximal ATP+Cr-P production) also promotes increased storage of FA as 
triacylglycerol (Figure 7E).  Glycerol for triacylglycerol synthesis is predicted to 
derive from conversion of glycolytic intermediates into glycerol-3-phosphate 
(glyc3P), as indicated by increased flux through glycerol-3-phosphate 
dehydrogenase (Figure 7H).   
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Table 6.  Major qualitative changes induced by increased glucose and fatty acid 
substrate availability (1xFA = 0.3838 mmol/L; 1xGluc = 5.0 mmol/L). 
 
Condition Major Qualitative Changes Compared to 1xFA1xGluc 
2xGluc Increased:  
 Glycolytic fluxes  
 Glycogen storage  
 TAG storage  
2xFA Increased: 
 TCA  
 OXPHOS  
 Glycogen storage  
 TAG storage  
2xFA-2xGluc Increased: 
 Glycolytic fluxes  
 TCA  
 OXPHOS  
 Glycogen storage  
 TAG storage  
 
 
Finally, increased availability of both glucose and fatty acids (2X Gluc, 2X FA, 
Table 6 and Figure 6D) largely produces effects reflecting a combination of effects 
from each nutrient independently.   
To further examine the impact of nutrient state on key parameters dysregulated in 
insulin resistance, I examined net ATP+Cr-P production, cumulative TCA cycle 
flux, and the RQ.  The increases in ATP+Cr-P production (Figure 5A) and TCA 
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flux (Figure 5B) during the transition from fasted to fed states are similar in each 
of the four different nutrient conditions (Figure 7A/B), paralleling oxygen 
consumption and OXPHOS flux (Figure 7F/G).  By contrast, nutrient availability 
has marked effects on RQ.  With increased glucose availability, there is a leftward 
shift in the respiratory quotient curve (Figure 7C), indicating increased glucose 
oxidation even in the fasting spectrum.  With increased FA availability, the RQ 
decreases, reflecting increased lipid oxidation. 
A. 
 
B. 
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C. 
 
D. 
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Figure 6. Fluxes through all reactions in the model from fasting to fed 
transition for four different nutrient states. 
Each row represents a reaction in the model, which are grouped and color-coded 
by pathway based on KEGG classification or manual curation.  Each column 
represents discrete sampling from the defined fasting to fed states, with colors 
indicating the flux through the reaction at each discretely sampled point. All zero 
fluxes across the entire spectrum were removed, and the remaining fluxes are 
normalized to the maximum flux specific to each row.  Red indicates that flux is 
proceeding in a positive direction (as indicated for each reaction in Supplemental 
File MuscleModelv1.1.pdf); green indicates flux in the opposite direction.  Nutrients 
taken into the system have a negative flux (green), while nutrients and metabolites 
produced and/or released have a positive flux (red).   (A) Normalized fluxes 
through each reaction based on substrate availability in the fasting state (1xFA-
1xGluc).  (B) Normalized fluxes with 2-fold increase in glucose availability (1xFA-
2xGluc).  (C) Normalized fluxes with 2-fold increase in fatty acid availability (2xFA-
1xGluc).  (D) Normalized fluxes with 2-fold increases in both glucose and fatty acid 
availability (2xFA-2xGluc). 
 
 
A. 
 
 
B. 
 
C. 
 
D. 
 
1xFA1xGluc 1xFA2xGluc 2xFA1xGluc 2xFA2xGluc
0
50
100
150
200
A
T
P
+
C
r-
P
 F
lu
x
 
(m
m
o
l/
L
/t
im
e
)
0
20
40
60
80
100
C
u
m
u
la
ti
ve
 T
C
A
  F
lu
x 
(m
m
o
l/
L/
ti
m
e
)
 
0.70
0.80
0.90
1.00
R
Q
 
0.0
2.0
4.0
6.0
8.0
G
ly
co
ge
n
 S
to
rg
ae
 F
lu
x 
(m
m
o
l/
L/
ti
m
e
)
52 
 
 
 
 
 
E. 
 
F. 
 
G. 
 
H. 
 
Figure 7. Predicted fluxes through pathways and substrate 
uptake/production.  Chart shows the flux in mmol/L/time on the Y-axis.  The x-
axis shows the flux at the discrete points from our defined fasting to fed states, as 
defined by conversely constraining the flux through CPT1 and modifiable glucose 
uptake from 0-100% of the maximum flux. The different nutrient states, defined in 
the text, are indicated by different colored lines and symbols: 1xFA/1xGluc 
(blue/diamonds), 1xFA/2xGluc (red/boxes), 2xFA/1xGluc (green/triangle), and 
2xFA/2xGluc (purple/x).  (A) Predicted ATP+Cr-P production, constrained to a 
maximum of 150 mmol/time (ATP limit 33.3 mmol/time; Cr-P limit 116.7 
mmol/time).  (B) Predicted cumulative flux through the TCA cycle, including citrate 
synthase, aconitase, isocitrate dehydrogenase-2, α-ketoglutarate dehydrogenase, 
succinyl coenzyme-A synthetase, succinate dehydrogenase, fumarase, and 
malate dehydrogenase-2 reactions. (C) Predicted respiratory quotient (RQ). (D) 
Predicted glycogen storage. (E) Predicted TAG storage.  (F) Predicted oxygen 
consumption.  (G) Cumulative flux through electron transport chain (complexes I-
V).  (H) Glucose oxidation, as measured by flux through glycerol-3-phosphate 
dehydrogenase (GPDH) reaction. 
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Simulating Metabolic Phenotypes of Insulin Resistance   
Given that the model recapitulated key aspects of muscle metabolism in different 
nutrient conditions across a simulated fasting to fed spectrum, I next utilized the 
model to determine if I could reproduce metabolic phenotypes associated with 
insulin resistance by systematically perturbing the flux in each of the 388 reactions 
in the model.  I performed in silico knockdowns (KD), defined as a 50% reduction 
in the normal (control) flux for each nutrient condition and state in the model 
(fasted, mixed, and fed) (Figure 3) and examined the impact of each KD on the 
three predefined insulin resistance phenotypes.  For ATP+Cr-P production or TCA 
cycle flux, a ratio (KD/control) less than one was considered to reflect insulin 
resistance.  I examined each knockdown’s impact on metabolic flexibility by 
determining whether the KD yielded an RQ pattern similar to insulin resistance 
(increased RQfasted and decreased RQfed).  Values indicating reduced RQ change 
in the fasting-fed transition (score >0) were considered to reflect insulin resistance, 
and significance determined by comparing data to the distribution of RQ changes 
(see Methods for more details). 
In the basal nutrient condition (1xFA-1xGluc), KDs in 34 reactions in the fasted 
state, 30 in the mixed state, and 26 in the fed state significantly reduced ATP+Cr-
P production (p<0.05, Table 7A). Top-ranking reactions included all OXPHOS 
complexes, NADH shuttling between cytosol and mitochondria, and TCA cycle.  In 
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addition, KDs in lipid and branched chain amino acid oxidation reduced ATP+Cr-
P production in the fasting and mixed, but not fed states, consistent with the more 
important role for these substrates in the fasting state.  KDs which reduced 
cumulative TCA cycle flux almost completely overlapped those influencing 
ATP+Cr-P production (Table 7B), consistent with TCA and OXPHOS as the 
dominant effectors of cellular energy production.   
 
 
Table 7. KDs in 1xFA-1xGluc causing significant reductions in the three screened 
phenotypes: ATP+Cr-P production, cumulative TCA flux, and metabolic 
inflexibility. 
 
Table 7A. KDs in 1xFA-1xGluc causing significant reductions in ATP+Cr-P production. 
ATP+Cr-P Fasted 
EC Number Reaction Score p 
n/a Nut_o2 0.53 0.00 
1.10.2.2 UCytC-III 0.53 0.00 
1.9.3.1 CytCO-IV 0.53 0.00 
3.6.3.14 ATPSynth-V 0.53 0.00 
1.5.5.1 ETFUO 0.63 0.00 
n/a Nut_co2 0.66 0.00 
1.3.99.1 SucDeh-II 0.67 0.00 
4.2.1.2 Fum 0.67 0.00 
1.1.1.37 MalDehM 0.67 0.00 
1.6.5.3 NADHDeh-I 0.68 0.00 
1.2.4.2 AKGDeh 0.68 0.00 
n/a CKM 0.69 0.00 
2.4.1.186/ 
2.4.1.11 
St_cr 0.69 0.00 
2.7.7.9 Nut_cr 0.69 0.00 
n/a Nut_p 0.70 0.00 
2.3.3.1 CitSynth 0.72 0.00 
4.2.1.3 Acon 0.72 0.00 
n/a Ex_pal 0.75 0.01 
n/a FAT-CD36 0.75 0.01 
6.2.1.3 ACSL/PalTK 0.75 0.01 
n/a SLC25A20-
CACT 
0.75 0.01 
2.3.1.21 CPT2 0.75 0.01 
1.3.99.3 AcylCoADeh 0.75 0.01 
4.2.1.17 EnoCoADeh 0.75 0.01 
1.1.1.35 3HA-CoADeh 0.75 0.01 
2.3.1.16 AcylCoAAT 0.75 0.01 
1.3.99.3 AcylCoADeh-
14-c 
0.78 0.02 
4.2.1.17 EnoCoADeh-
14c 
0.78 0.02 
1.1.1.35 3HA-CoADeh-
14c 
0.78 0.02 
2.3.1.16 AcylCoAAT-
14c 
0.78 0.02 
1.3.99.3 AcylCoADeh-
12-c 
0.82 0.05 
ATP+Cr-P Mixed 
EC Number Reaction Score p 
n/a Nut_o2 0.54 0.00 
1.10.2.2 UCytC-III 0.54 0.00 
1.9.3.1 CytCO-IV 0.54 0.00 
3.6.3.14 ATPSynth-V 0.53 0.00 
1.2.1.12 D3PDeh 0.64 0.00 
2.7.2.3 PGK 0.64 0.00 
1.1.1.37 MalDehM 0.60 0.00 
n/a CKM 0.62 0.00 
2.4.1.186/ 
2.4.1.11 
St_cr 0.62 0.00 
2.7.7.9 Nut_cr 0.62 0.00 
n/a MalDehC 0.68 0.00 
n/a Mal-AKGEX 0.68 0.00 
1.6.5.3 NADHDeh-I 0.64 0.00 
n/a Nut_p 0.64 0.00 
n/a ASTC 0.73 0.00 
n/a Glu-AspEx 0.73 0.00 
2.6.1.1 ASTM 0.73 0.00 
n/a Nut_co2 0.64 0.00 
n/a Ex_gluc 0.64 0.00 
2.7.1.2 Hex 0.64 0.00 
n/a MCT 0.73 0.00 
1.2.4.1 PyrSynth-
pdh 
0.78 0.02 
1.3.99.1 SucDeh-II 0.69 0.00 
4.2.1.2 Fum 0.69 0.00 
1.2.4.2 AKGDeh 0.69 0.00 
1.5.5.1 ETFUO 0.70 0.00 
2.3.3.1 CitSynth 0.71 0.00 
4.2.1.3 Acon 0.71 0.00 
 
ATP+Cr-P Fed 
EC Number Reaction Score p 
n/a Nut_o2 0.56 0.00 
1.10.2.2 UCytC-III 0.56 0.00 
1.9.3.1 CytCO-IV 0.56 0.00 
3.6.3.14 ATPSynth-
V 
0.56 0.00 
1.2.1.12 D3PDeh 0.58 0.00 
2.7.2.3 PGK 0.58 0.00 
1.1.1.37 MalDehM 0.59 0.00 
 CKM 0.61 0.00 
2.4.1.186/ 
2.4.1.11 
St_cr 0.61 0.00 
2.7.7.9 Nut_cr 0.61 0.00 
n/a MalDehC 0.64 0.00 
n/a Mal-
AKGEX 
0.64 0.00 
1.6.5.3 NADHDeh
-I 
0.65 0.00 
n/a Nut_p 0.67 0.00 
n/a ASTC 0.68 0.00 
n/a Glu-AspEx 0.68 0.00 
2.6.1.1 ASTM 0.68 0.00 
n/a Nut_co2 0.70 0.00 
n/a Ex_gluc 0.74 0.00 
2.7.1.2 Hex 0.74 0.00 
n/a MCT 0.75 0.00 
1.2.4.1 PyrSynth-
pdh 
0.80 0.02 
1.3.99.1 SucDeh-II 0.82 0.04 
4.2.1.2 Fum 0.82 0.04 
1.2.4.2 AKGDeh 0.83 0.04 
1.5.5.1 ETFUO 0.83 0.04 
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4.2.1.17 EnoCoADeh-
12c 
0.82 0.05 
1.1.1.35 3HA-CoADeh-
12c 
0.82 0.05 
2.3.1.16 AcylCoAAT-
12c 
0.82 0.05 
 
 
Table 7B. KDs in 1xFA-1xGluc causing significant reductions in cumulative TCA flux. 
TCA Fasted 
EC Number Reaction Score p 
n/a Nut_o2 0.50 0.00 
1.10.2.2 UCytC-III 0.50 0.00 
1.9.3.1 CytCO-IV 0.50 0.00 
3.6.3.14 ATPSynth-V 0.51 0.00 
1.2.4.2 AKGDeh 0.57 0.00 
1.3.99.1 SucDeh-II 0.57 0.00 
4.2.1.2 Fum 0.57 0.00 
1.5.5.1 ETFUO 0.60 0.00 
n/a Nut_co2 0.60 0.00 
4.2.1.3 Acon 0.66 0.00 
2.3.3.1 CitSynth 0.66 0.00 
1.1.1.37 MalDehM 0.66 0.00 
1.6.5.3 NADHDeh-I 0.70 0.00 
2.7.7.9 Nut_cr 0.71 0.00 
 CKM 0.71 0.00 
2.4.1.186/ 
2.4.1.11 
St_cr 0.71 0.00 
n/a Ex_pal 0.74 0.01 
n/a FAT-CD36 0.74 0.01 
6.2.1.3 ACSL/PalTK 0.74 0.01 
n/a SLC25A20-CACT 0.74 0.01 
2.3.1.21 CPT2 0.74 0.01 
1.3.99.3 AcylCoADeh 0.74 0.01 
4.2.1.17 EnoCoADeh 0.74 0.01 
1.1.1.35 3HA-CoADeh 0.74 0.01 
2.3.1.16 AcylCoAAT 0.74 0.01 
1.3.99.3 AcylCoADeh-14-c 0.77 0.02 
4.2.1.17 EnoCoADeh-14c 0.77 0.02 
1.1.1.35 3HA-CoADeh-14c 0.77 0.02 
2.3.1.16 AcylCoAAT-14c 0.77 0.02 
4.2.1.17 EnoCoADeh-12c 0.81 0.04 
1.1.1.35 3HA-CoADeh-12c 0.80 0.04 
 
TCA Mixed 
EC Number Reaction Score p 
n/a Nut_o2 0.46 0.00 
1.10.2.2 UCytC-III 0.46 0.00 
1.9.3.1 CytCO-IV 0.46 0.00 
3.6.3.14 ATPSynth-V 0.52 0.00 
1.2.4.2 AKGDeh 0.57 0.00 
1.3.99.1 SucDeh-II 0.57 0.00 
4.2.1.2 Fum 0.57 0.00 
1.1.1.37 MalDehM 0.58 0.00 
n/a Nut_co2 0.59 0.00 
4.2.1.3 Acon 0.63 0.00 
2.3.3.1 CitSynth 0.63 0.00 
2.7.7.9 Nut_cr 0.64 0.00 
n/a CKM 0.64 0.00 
2.4.1.186/ 
2.4.1.11 
St_cr 0.64 0.00 
n/a Ex_gluc 0.64 0.00 
1.2.1.12 D3PDeh 0.64 0.00 
2.7.2.3 PGK 0.64 0.00 
2.7.1.2 Hex 0.64 0.00 
1.6.5.3 NADHDeh-I 0.65 0.00 
1.5.5.1 ETFUO 0.67 0.00 
n/a MalDehC 0.67 0.00 
n/a Mal-AKGEX 0.67 0.00 
n/a MCT 0.69 0.00 
n/a ASTC 0.72 0.01 
n/a Glu-AspEx 0.72 0.01 
2.6.1.1 ASTM 0.72 0.01 
1.2.4.1 PyrSynth-pdh 0.80 0.02 
 
TCA Fed 
EC Number Reaction Score p 
n/a Nut_o2 0.51 0.00 
1.10.2.2 UCytC-III 0.51 0.00 
1.9.3.1 CytCO-IV 0.51 0.00 
3.6.3.14 ATPSynth-V 0.53 0.00 
1.1.1.37 MalDehM 0.55 0.00 
1.2.1.12 D3PDeh 0.56 0.00 
2.7.2.3 PGK 0.56 0.00 
n/a MalDehC 0.59 0.00 
n/a Mal-AKGEX 0.59 0.00 
1.2.4.2 AKGDeh 0.61 0.00 
1.3.99.1 SucDeh-II 0.61 0.00 
4.2.1.2 Fum 0.61 0.00 
n/a Nut_co2 0.61 0.00 
1.6.5.3 NADHDeh-I 0.63 0.00 
2.7.7.9 Nut_cr 0.63 0.00 
n/a CKM 0.63 0.00 
2.4.1.186/ 
2.4.1.11 
St_cr 0.63 0.00 
n/a ASTC 0.64 0.00 
n/a Glu-AspEx 0.64 0.00 
2.6.1.1 ASTM 0.64 0.00 
1.5.5.1 ETFUO 0.65 0.00 
n/a MCT 0.66 0.00 
2.3.3.1 CitSynth 0.67 0.00 
4.2.1.3 Acon 0.67 0.00 
n/a Ex_gluc 0.72 0.01 
2.7.1.2 Hex 0.72 0.01 
1.2.4.1 PyrSynth-
pdh 
0.73 0.01 
 
 
 
Table 7C. KDs in 1xFA-1xGluc 
causing significant reductions in 
metabolic flexibility as measured by 
RQ differences. 
EC Number Reaction Score p 
1.2.4.1 PyrSynth-pdh -0.09 0.01 
n/a Ex_pal -0.03 0.43 
n/a FAT-CD36 -0.03 0.43 
6.2.1.3 ACSL/PalTK -0.03 0.43 
n/a Glu-AspEx -0.01 0.71 
2.6.1.1 ASTM -0.01 0.71 
n/a ASTC -0.01 0.73 
n/a NEAA_asp 0.00 0.88 
 
 
By contrast, KDs of only one reaction significantly reduced metabolic flexibility:  
pyruvate dehydrogenase (PDH) (Table 7C).  All other candidates were not 
statistically significant: fatty acid transport (e.g., Ex_pal; FAT-CD36), long-chain 
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acyl-CoA synthase (ACSL), glutamate-aspartate mitochondrial exchange 
(GLAST), and both cytosolic and mitochondrial aspartate transaminase (AST) 
(Table 7C). These reactions are key regulatory nodes for glucose metabolism, lipid 
uptake and metabolism, aspartate metabolism, and the transport of extra-
mitochondrial hydrogen to the respiratory chain.  KDs of these also reduced 
ATP+Cr-P production and cumulative TCA flux (Table 8).   
 
Table 8. Top KDs causing reduced metabolic flexibility in basal nutrient condition 
(1xFA-1xGluc).  For metabolic flexibility, data indicate cumulative difference in RQ 
(Eq. 8 in text).  For each KD, data indicate ratio of KD compared to control (Eq. 6 
and 7 in text).  
KD 
Reaction 
EC 
Number 
Met. Flex ATP+Cr-P Production Cumulative TCA Flux 
 RQ Fasted Mixed Fed Fasted Mixed Fed 
PDH 1.2.4.1 0.09 0.94 0.78 0.80 0.93 0.77 0.73 
FAT-CD36 n/a 0.03 0.75 0.92 1.00 0.74 0.91 1.00 
PalTK 6.2.1.3 0.03 0.75 0.92 1.00 0.74 0.91 1.00 
ASTM 2.6.1.1 0.01 0.96 0.73 0.68 0.97 0.91 0.64 
ASTC n/a 0.01 0.95 0.73 0.68 0.96 0.72 0.64 
Glu-Asp Ex n/a 0.01 0.96 0.73 0.68 0.97 0.72 0.64 
 
With increased nutrient availability (2xFA-2xGluc), the model predicts that the 
objective functions (ATP, Cr-P, glycogen and TG storage) can be achieved more 
readily.  In agreement, fewer KDs produce insulin resistance phenotypes.  
Significant reductions in ATP+Cr-P  production were observed with 31 KDs in 
fasting, 18 in mixed, and 17 in the fed state (Table 9A), with similar patterns for 
TCA flux (Table 9B).  Once again, only the KD in PDH yielded significant 
alterations in respiratory quotient; similar trends were observed for FAT and ACSL 
(Tables 9C and 10).  
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Table 9. KDs in 2xFA-2xGluc causing significant reductions in the three screened 
phenotypes: ATP+Cr-P production, cumulative TCA flux, and metabolic 
inflexibility. 
 
Table 9A. KDs in 2xFA-2xGluc causing significant reductions in ATP+Cr-P production. 
ATP+Cr-P Fasted 
EC Number Reaction Score p 
3.6.3.14 ATPSynth-V 0.53 2.1E-07 
n/a Nut_o2 0.53 2.9E-07 
1.10.2.2 UCytC-III 0.53 2.9E-07 
1.9.3.1 CytCO-IV 0.53 2.9E-07 
n/a CKM 0.61 1.9E-05 
2.4.1.186/ 
2.4.1.11 
St_cr 0.61 1.9E-05 
2.7.7.9 Nut_cr 0.61 1.9E-05 
n/a Nut_p 0.63 4.2E-05 
1.5.5.1 ETFUO 0.65 9.6E-05 
n/a Nut_co2 0.67 0.00025 
1.1.1.37 MalDehM 0.67 0.00028 
1.6.5.3 NADHDeh-I 0.68 0.00045 
1.3.99.1 SucDeh-II 0.69 0.00054 
4.2.1.2 Fum 0.69 0.00054 
1.2.4.2 AKGDeh 0.69 0.00064 
2.3.3.1 CitSynth 0.71 0.0014 
4.2.1.3 Acon 0.71 0.0014 
2.3.1.21 CPT1B-CHKL 0.77 0.012 
n/a SLC25A20-
CACT 
0.77 0.012 
2.3.1.21 CPT2 0.77 0.012 
1.3.99.3 AcylCoADeh 0.77 0.012 
4.2.1.17 EnoCoADeh 0.77 0.012 
1.1.1.35 3HA-CoADeh 0.77 0.012 
2.3.1.16 AcylCoAAT 0.77 0.012 
n/a Ex_pal 0.81 0.031 
n/a FAT-CD36 0.81 0.031 
6.2.1.3 ACSL/PalTK 0.81 0.031 
1.3.99.3 AcylCoADeh- 
14-c 
0.81 0.036 
4.2.1.17 EnoCoADeh-
14c 
0.81 0.036 
1.1.1.35 3HA-CoADeh-
14c 
0.81 0.036 
2.3.1.16 AcylCoAAT-14c 0.81 0.036 
 
ATP+Cr-P Mixed 
EC Number Reaction Score p 
3.6.3.14 ATPSynth-V 0.60 5.4E-10 
n/a Nut_o2 0.60 9.9E-10 
1.10.2.2 UCytC-III 0.60 9.9E-10 
1.9.3.1 CytCO-IV 0.60 9.9E-10 
n/a CKM 0.61 2.8E-09 
2.4.1.186/ 
2.4.1.11 
St_cr 0.61 2.8E-09 
2.7.7.9 Nut_cr 0.61 3.0E-09 
1.1.1.37 MalDehM 0.69 1.6E-06 
n/a Nut_p 0.69 1.6E-06 
1.6.5.3 NADHDeh-I 0.72 1.6E-05 
1.2.1.12 D3PDeh 0.74 5.1E-05 
2.7.2.3 PGK 0.74 5.1E-05 
n/a MalDehC 0.82 0.0039 
n./a Mal-AKGEX 0.82 0.0039 
n/a Nut_co2 0.84 0.011 
n/a ASTC 0.86 0.022 
n/a Glu-AspEx 0.86 0.024 
2.6.1.1 ASTM 0.856 0.024 
 
ATP+Cr-P Fed 
EC Number Reaction Score p 
n/a CKM 0.61 2.8E-09 
2.4.1.186/ 
2.4.1.11 
St_cr 0.61 2.8E-09 
2.7.7.9 Nut_cr 0.61 3.0E-09 
1.2.1.12 D3PDeh 0.63 1.2E-08 
2.7.2.3 PGK 0.63 1.2E-08 
n/a Nut_o2 0.66 1.5E-07 
1.10.2.2 UCytC-III 0.66 1.5E-07 
1.9.3.1 CytCO-IV 0.66 1.5E-07 
3.6.3.14 ATPSynth-V 0.66 1.7E-07 
1.1.1.37 MalDehM 0.69 2.8E-06 
n/a Nut_p 0.75 9.0E-05 
n/a MalDehC 0.75 0.00014 
n/a Mal-AKGEX 0.75 0.00014 
1.6.5.3 NADHDeh-I 0.76 0.00017 
n/a ASTC 0.79 0.0014 
n/a Glu-AspEx 0.80 0.0016 
2.6.1.1 ASTM 0.80 0.0016 
 
 
Table 9B. KDs in 2xFA-2xGluc causing significant reductions in cumulative TCA flux. 
TCA Fasted 
EC Number Reaction Score p 
n/a Nut_o2 0.50 4.6E-07 
1.10.2.2 UCytC-III 0.50 4.6E-07 
1.9.3.1 CytCO-IV 0.50 4.6E-07 
3.6.3.14 ATPSynth-V 0.51 5.7E-07 
1.2.4.2 AKGDeh 0.55 5.8E-06 
1.3.99.1 SucDeh-II 0.55 5.8E-06 
4.2.1.2 Fum 0.55 5.8E-06 
n/a Nut_co2 0.60 5.7E-05 
4.2.1.3 Acon 0.60 6.4E-05 
2.3.3.1 CitSynth 0.61 6.8E-05 
1.5.5.1 ETFUO 0.62 0.0001
0 
n/a CKM 0.64 0.0002
4 
2.4.1.186/ 
2.4.1.11 
St_cr 0.64 0.0002
4 
TCA Mixed 
EC Number Reaction Score p 
3.6.3.14 ATPSynth-V 0.52 1.5E-07 
n/a Nut_o2 0.52 1.6E-07 
1.10.2.2 UCytC-III 0.52 1.6E-07 
1.9.3.1 CytCO-IV 0.52 1.6E-07 
1.1.1.37 MalDehM 0.61 2.3E-05 
1.2.4.2 AKGDeh 0.64 9.6E-05 
1.3.99.1 SucDeh-II 0.64 9.6E-05 
4.2.1.2 Fum 0.64 9.6E-05 
2.7.7.9 Nut_cr 0.65 0.00013 
n/a CKM 0.65 0.00013 
2.4.1.186/ 
2.4.1.11 
St_cr 0.65 0.00013 
1.6.5.3 NADHDeh-I 0.67 0.00029 
4.2.1.3 Acon 0.69 0.00065 
2.3.3.1 CitSynth 0.69 0.00069 
n/a Nut_co2 0.69 0.00074 
1.2.1.12 D3PDeh 0.71 0.0014 
TCA Fed 
EC Number Reaction Score p 
n/a Nut_o2 0.51 3.3E-05 
1.10.2.2 UCytC-III 0.51 3.3E-05 
1.9.3.1 CytCO-IV 0.51 3.3E-05 
3.6.3.14 ATPSynth-
V 
0.53 6.3E-05 
1.1.1.37 MalDehM 0.55 0.00016 
1.2.1.12 D3PDeh 0.58 0.00032 
2.7.2.3 PGK 0.58 0.00032 
n/a MalDehC 0.61 0.00092 
n/a Mal-AKGEX 0.61 0.00092 
1.6.5.3 NADHDeh-I 0.63 0.0017 
n/a ASTC 0.65 0.0028 
1.2.4.2 AKGDeh 0.65 0.0029 
1.3.99.1 SucDeh-II 0.65 0.0030 
4.2.1.2 Fum 0.65 0.0030 
n/a Glu-AspEx 0.65 0.0030 
2.6.1.1 ASTM 0.65 0.0030 
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2.7.7.9 Nut_cr 0.64 0.0002
5 
1.1.1.37 MalDehM 0.65 0.0003
5 
1.6.5.3 NADHDeh-I 0.70 0.0028 
2.3.1.21 CPT1B-CHKL 0.76 0.014 
n/a SLC25A20-
CACT 
0.76 0.014 
2.3.1.21 CPT2 0.76 0.014 
1.3.99.3 AcylCoADeh 0.76 0.014 
4.2.1.17 EnoCoADeh 0.76 0.014 
1.1.1.35 3HA-CoADeh 0.76 0.014 
2.3.1.16 AcylCoAAT 0.76 0.014 
n/a Ex_pal 0.79 0.033 
n/a FAT-CD36 0.79 0.033 
6.2.1.3 ACSL/PalTK 0.79 0.033 
1.3.99.3 AcylCoADeh-
14-c 
0.80 0.037 
4.2.1.17 EnoCoADeh-
14c 
0.80 0.037 
1.1.1.35 3HA-CoADeh-
14c 
0.80 0.037 
2.3.1.16 AcylCoAAT-
14c 
0.80 0.037 
 
2.7.2.3 PGK 0.71 0.0014 
n/a MalDehC 0.74 0.0040 
n/a Mal-AKGEX 0.74 0.0040 
n/a ASTC 0.78 0.014 
n/a Glu-AspEx 0.78 0.015 
2.6.1.1 ASTM 0.78 0.015 
1.5.5.1 ETFUO 0.80 0.022 
 
2.7.7.9 Nut_cr 0.66 0.0032 
n/a CKM 0.66 0.0032 
2.4.1.186/ 
2.4.1.11 
St_cr 0.66 0.0032 
2.3.3.1 CitSynth 0.70 0.0088 
4.2.1.3 Acon 0.70 0.0088 
1.5.5.1 ETFUO 0.70 0.0088 
n/a Nut_co2 0.73 0.019 
n/a MCT 0.7 0.037 
 
 
Table 9C. KDs in 2xFA-2xGluc 
causing significant reductions in 
metabolic flexibility as measured by 
RQ differences. 
EC Number Reaction Score p 
1.2.4.1 PyrSynth-pdh -0.22 0.0004 
n/a Ex_pal -0.046 0.21 
n/a FAT-CD36 -0.046 0.21 
6.2.1.3 ACSL/PalTK -0.046 0.21 
 
 
 
 
 
Table 10.  Top KDs causing reduced metabolic flexibility in the 2xFA-2xGluc 
increased nutrient condition.  For metabolic flexibility, data indicate cumulative 
difference in RQ (Eq. 8 in text). For each KD, data indicate ratio of KD compared 
to control (Eq. 6 and 7 in text). 
KD 
Reaction 
EC 
Number 
Met. Flex ATP+Cr-P Production Cumulative TCA Flux 
RQ Fasted Mixed Fed Fasted Mixed Fed 
PDH 1.2.4.1 0.22 0.96 0.78 0.80 0.96 0.90 0.82 
FAT-CD36 n/a 0.05 0.81 1.00 1.00 0.74 1.00 1.00 
ACSL/PalTK 6.2.1.3  0 0.81 1.00 1.00 0.74 1.00 1.00 
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Pathway Analysis of Knockdown Phenotypes  
To determine whether experimental alterations in flux within specific metabolic 
pathways were more likely to yield insulin resistance phenotypes, I performed a 
pathway-based analysis.   I used Fisher’s exact test and the Benjamini-Hochberg 
method to assess significance and calculate false discovery rate (FDR), 
respectively. 
In the control nutrient state, three pathways were significantly enriched for 
reduction in ATP+Cr-P production (p<0.05, Q<0.25) in the fasting and mixed 
conditions: BCAA, butanoate, and lysine metabolism (Table 11).  Similarly, seven 
pathways were significantly enriched for reducing TCA flux: BCAA, butanoate, 
lysine, propanoate, tryptophan, FAD metabolism, and the TCA cycle itself.  Only 
three pathways were enriched for reductions in metabolic flexibility: 
glycerophospholipid metabolism, lysine metabolism, and NADH shuttle. 
Table 11. Pathways enriched in causing IR phenotypes (p < 0.05; Q < 0.25) in 
1xFA-1xGluc basal nutrient condition. 
 
ATP + Cr-P Production Cumulative TCA Flux Metabolic Inflexibility 
 BCAA (fast and mixed) 
 Butanaote (fast and mixed) 
 Lysine (fast and mixed) 
 
 BCAA (fast and mixed) 
 Butanaote (fast and mixed) 
 Lysine (fast and mixed) 
 Propanoate (fast and mixed) 
 TCA Cycle (fast only) 
 Tryptophan (fast and mixed) 
 FAD metabolism (fast only) 
 Glycerophospholipid 
 Lysine 
 NADH shuttle 
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Increasing glucose and fatty acid availability (2xFA-2xGluc) yielded similar 
pathway results.  OXPHOS, TCA cycle, glycolysis, fatty acid metabolism, and the 
NADH shuttle remained significantly enriched for modulating ATP+Cr-P 
production, while the BCAA pathway was no longer significantly enriched.  
Similarly, increased nutrient availability (2xFA-2xGluc) also reduced the number of 
pathways significantly enriched for reduced-cumulative-TCA-flux phenotype: 
glycerophospholipid, glycolysis, lysine, OXPHOS, and NADH shuttle.  The only 
pathway enriched (p<0.05) for reduced metabolic flexibility under conditions of 
increased glucose and fatty acid availability was glycerophospholipid metabolism, 
but the FDR value (Q = 0.73) was above the threshold (Table 12). 
 
Table 12. Pathways enriched in causing IR phenotypes (p < 0.05; Q < 0.25, 
except otherwise indicated) in the 2xFA-2xGluc increased nutrient condition. 
 
ATP + Cr-P Production Cumulative TCA Flux Metabolic Inflexibility 
 Fatty Acid Metabolism 
(Fasted only) 
 Glycolysis (fasted only) 
 OXPHOS (fasted and 
mixed) 
 TCA Cycle (fasted and 
mixed) 
 NADH Shuttle (fasted 
and mixed) 
 Glycerolipid/glycerophospholipid 
(fasted and mixed) 
 Glycolysis (fasted and mixed) 
 Lysine (fasted only) 
 OXPHOS (fasted and mixed) 
 NADH Shuttle (fasted and mixed) 
 Glycerophospholipid (p< 
0.05; Q = 0.73) 
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Multiple Simultaneous Knockdowns are Required to Fully Recapitulate 
Metabolic Phenotypes Associated with Insulin Resistance  
It is notable that reduced flux in any single reaction did not produce all three 
metabolic phenotypes associated with insulin resistance in all conditions sampled.  
This is potentially an important observation, and if true in biological systems, it is 
likely a result of the extensive redundancy in cellular metabolism.  Thus, I next 
asked whether simultaneous KDs in more than one reaction could more readily 
induce insulin resistance phenotypes.  I performed a KD for each of the top three 
reactions causing decreased metabolic flexibility (PDH, FAT, and AST) and then 
systematically performed a second knockdown of all other reactions in 
combination. Interestingly, two knockdown pairs, either PDH and electron-
transferring-flavoprotein dehydrogenase (ETFD), or PDH and FAT, did reduce 
ATP+Cr-P production and cumulative TCA flux and induce metabolic inflexibility 
(Figure 8, open shapes).  While the PDH&ETFD and PDH&FAT double KDs both 
led to the insulin resistance phenotype in the 1xFA-1xGluc nutrient state, the 
PDH&ETFD double KD was the only combination which recapitulated all three 
insulin resistance phenotypes in all four nutrient conditions. By contrast, other 
combinations were not as robust at recapitulating the phenotypes in each condition 
(Table 13).    
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A. 
 
 
B.
 
C. 
 
Figure 8. Combined knockdowns can induce metabolic phenotypes 
associated with insulin resistance.  (A) ATP + Cr-P storage and (B) TCA cycle 
flux, and (C) respiratory quotient (RQ) under control conditions and in response to 
single or combined knockdowns.    
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Table 13. Summary of scores for the top DOUBLE KDs causing reduced 
metabolic flexibility.  For metabolic flexibility, data indicate cumulative difference 
in RQ (Eq. 8 in text). For each KD, data indicate ratio of KD compared to control 
(Eq. 6 and 7 in text).  
 
Table 13A. Basal nutrient condition (1xFA-1xGluc) 
KD 
Reactions 
EC 
Numbers 
Met. Flex ATP+Cr-P Production Cumulative TCA Flux 
 RQ Fasted Mixed Fed Fasted Mixed Fed 
PDH & ETFD 
1.2.4.1 & 
1.5.5.1 
0.21 0.58 0.61 0.70 0.55 0.56 0.61 
PDH & FAT-
CD36 
1.2.4.1 &    
n/a 
0.16 0.69 0.71 0.80 0.65 0.68 0.73 
PDH & ASN 
Synth 
1.2.4.1 & 
2.7.2.11 
0.15 0.94 0.76 0.78 0.93 0.73 0.69 
FAT-CD36 & 
MCT 
n/a    &    
n/a 
0.29 0.68 0.66 0.75 0.61 0.60 0.66 
AST & FAT-
CD36 
2.6.1.1 &    
n/a 
0.10 0.73 0.65 0.68 0.69 0.62 0.63 
AST & ETFD 
2.6.1.1 & 
1.5.5.1 
0.06 0.60 0.58 0.61 0.58 0.59 0.58 
 
 
Table 13B. Increased nutrient condition (2xFA-2xGluc) 
KD 
Reactions 
EC 
Numbers 
Met. Flex ATP+Cr-P Production Cumulative TCA Flux 
 RQ Fasted Mixed Fed Fasted Mixed Fed 
PDH & ETFD 
1.2.4.1 & 
1.5.5.1 
0.32 0.58 0.78 0.98 0.53 0.63 0.73 
PDH & FAT-
D36 
1.2.4.1 &    
n/a 
0.37 0.72 1.00 1.00 0.66 0.90 0.82 
PDH & ASN 
Synth 
1.2.4.1 & 
2.7.2.11 
0.24 0.96 1.00 1.00 0.92 0.86 0.79 
FAT-CD36 & 
MCT 
n/a    &    n/a 0.41 0.68 0.98 1.00 0.60 0.83 0.77 
AST & FAT-
CD36 
2.6.1.1 &   
n/a 
0.15 0.71 0.85 0.79 0.65 0.77 0.64 
AST & ETFD 
2.6.1.1 & 
1.5.5.1 
0.02 0.57 0.64 0.70 0.55 0.62 0.58 
 
 
Interestingly, the combination of reduced flux through PDH&ETFD or PDH&FAT 
also produced other phenotypes associated with insulin resistance.  KDs in PDH 
decreased PDH activity, as expected, but also increased non-oxidized pyruvate 
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(lactate) production (Figures 9A and 9B); this was most striking with the 
PDH&ETFD combination.  Similarly, the model predicts that a KD in PDH or ETFD 
alone or in combination, or combined KD in PDH& FAT lead to reduced glycogen 
storage – also a key phenotype of insulin resistance (Eriksson et al., 1989) (Figure 
9C).   Strikingly, double KDs in PDH&ETFD or PDH&FAT reduce complete fatty 
acid oxidation (Figure 9D) and increase release of short-chain acyl-carnitines 
(Figure 9E), suggesting incomplete fatty acid oxidation, as described in both 
humans and rodents with insulin resistance (Koves et al., 2008).  I also observed 
reduced TAG storage with this combination (Figure 9F), and found reduced TAG 
storage in the increased nutrient conditions (2xFA1xGluc, 1xFA2xGluc, and 
2xFA2xGluc) with the PDH&ETFD double KD.   
A. 
 
B. 
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H. 
 
I. 
 
Figure 9.  Double knockdowns (PDH/ETFDH or PDH/FAT) alter carbohydrate 
and fatty acid metabolism, including (A) PDH activity, (B) reduced non-oxidized 
pyruvate, (C) reduced glycogen storage, (D) reduced complete fatty acid oxidation,  
(E) increased release of short-chain acyl-carnitines. (F) 1xFA1xGluc TAG Storage 
Flux, (G) 1xFA12Gluc TAG Storage Flux, (H) 2xFA1xGluc TAG Storage Flux, and 
(I) 2xFA2xGluc TAG Storage Flux 
 
Biological Validation of In Silico Results 
RT-PCR of candidate genes from skeletal muscle cells from IR 
induced mice show altered gene expression  
In silico predictions and FBA modeling provide insight into the possible metabolic 
dysregulations which cause the metabolic alterations observed in IR phenotypes.  
However, the next step is to use these predictions to help design in vivo/vitro 
experiments to validate these predictions/simulations.  Yi et al. (2013) recently 
published a mouse model where IR is induced by a small peptide S961 (43 amino 
acids in length). S961 binds the insulin receptor in mice and antagonizes the insulin 
signaling pathway.  After a week of S961 treatment, mice become hyperglycemic 
and glucose intolerant (Yi et al, 2013). To examine the impact of acute IR-induction 
0
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on expression of candidate enzymes identified by the in silico analysis, mice were 
treated with 10 nMol/week S961 or PBS, and RT-PCR was performed for the 
genes which encode for the candidate enzymes: PDH, ETFDH, and FAT/CD36.8  
Of the genes tested PDHb, ETFb, and CD36 had significantly lower expression 
levels in skeletal muscle cells which were S961 treated compared to the PBS 
group (p<0.05).  The expression in S961 treated group for genes PDHA1 and 
FATP2, while not significant (0.05>p<0.10), trended lower than control (Table 14).   
Table 149.  RT-PCR results from skeletal muscle tissue from the Control (PBS) 
and S961 IR induced mice for candidate genes from in silico analysis.  
Gene: ETFDH ETFa ETFb* PDHa1¥ PDHa2 PDHb* PDHx CD36* FATP1 FATP2¥ 
PBS 
(control) 
1.04 
+0.15 
1.03 
+0.13 
1.05 
+0.17 
1.01 
+0.08 
1.13 
+0.28 
1.08 
+0.23 
1.03 
+0.12 
1.02 
+0.11 
1.02 
+0.10 
1.06 
+0.20 
S961 
treated 
0.91 
+0.15 
0.91 
+0.14 
0.59 
+0.14* 
0.78 
+0.13¥ 
2.18 
+0.80 
0.64 
+0.09* 
0.82 
+0.12 
0.66 
+0.10* 
0.86 
+0.21 
0.66 
+0.15¥ 
*p < 0.05; ¥p<0.10 (1-tailed t-test) 
Lower PDH protein expression and siRNA ETFDH Knockdown Cause 
IR-like Phenotypes from Mouse Myotubes 
To determine if alterations in flux through the enzymes identified in our in silico 
analysis would also recapitulate IR metabolic phenotypes in vivo, we analyzed the 
impact of modulating candidate genes in mouse myocytes.    Given the difficulty in 
establishing robust knockdowns of two genes in combination using siRNA, we 
utilized primary myoblasts derived from mice in which PDH flux was decreased by 
dual genetic ablation of the PDH inhibitors pyruvate dehydrogenase kinase 2/4 
                                            
 
8 Ana-Luisa Coelho, PhD, extracted gastrocnemius tissue and performed RT-PCR. 
9 Alison Burkart, PhD, collected and analyzed the data in this table. 
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(PDK2/4). Pyruvate dehydrogenase kinase (PDK) is an important regulatory 
enzyme of PDH, deactivating PDH via phosphorylation (Bowker-Kinley et al. 
1998).  Without PDK’s inhibitory effect, PDH phosphorylation and flux are 
increased, as compared to WT cells (Figure 10A); thus, PDK 2/4-KO and WT cells 
allow analysis of the metabolic impact of relative reductions in PDH activity. We 
then superimposed siRNA-mediated KD of ETFDH in PDK2/4 KO and WT cells to 
examine the impact of decreased activity of both candidate enzymes, 
independently and in combination.  We confirmed decreased mRNA expression of 
PDK2/4 and ETFDH by qRT-PCR analysis (Figure 10B).  Similarly, Western blots 
demonstrated reduced PDH phosphorylation in PDK2/4-KO cells and reduced 
ETFDH protein expression in cells transfected with ETFDH siRNA (Figure 10C). 
After confirming successful experimental knockdowns, we analyzed IR-associated 
metabolic phenotypes.  We first measured ATP levels; consistent with model 
predictions, cells with lower PDH activity (WT) had significantly lower ATP content 
(Figure 10D). Although KD of ETFDH alone did not significantly reduce ATP 
levels, ATP levels were significantly lower with combined reduction in PDH and 
ETFDH activity.   (Figure 10D).    We next examined flux through the TCA cycle 
by analyzing the activity of the key TCA cycle enzyme citrate synthase (CS), a key 
TCA cycle enzyme.  Myoblasts with lower PDH activity had decreased CS activity, 
and ETFDH siRNA reduced CS activity (Figure 10E). 
To determine the impact of experimental manipulation of PDH and ETFDH on 
metabolic flexibility, we assessed cellular substrate utilization and responses to 
69 
 
 
nutrient modulation.  Specifically, we measured extracellular acidification rate 
(ECAR), a readout of glycolytic glucose metabolism, and oxygen consumption rate 
(OCR), a measure of aerobic respiration, and determined the ECAR/OCR ratio as 
a surrogate for substrate utilization.  In the fasted state, lipid substrate utilization 
would dominate, with more oxygen consumption and less glycolysis, yielding a 
lower ECAR/OCR ratio.  By contrast, in the fed state, the ECAR/OCR ratio is 
higher, consistent with predominant glucose utilization.  To assess metabolic 
flexibility, or the ability of cells to modulate substrate utilization, cells were 
incubated with palmitate (to promote lipid oxidation) and then acutely treated with 
glucose to provoke a switch from lipid to carbohydrate metabolism. As expected, 
glucose increased the ECAR/OCR ratio, consistent with a shift to glycolytic 
metabolism (Figure 10F). Consistent with model predictions, cells with lower PDH 
flux displayed a reduced shift to glycolytic metabolism (decreased slope of 
ECAR/OCR change) upon addition of glucose, as compared to cells with higher 
PDH flux. Moreover, knockdown of ETFDH tended to reduce this shift (Figure 
10F).  Thus, experimental reductions in PDH and ETFDH flux result in reduced 
metabolic flexibility. 
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Figure 10. Double knockdowns in myoblasts recapitulate the IR phenotypes 
predicted by in silico experiments. PDK2/4 wild type and knockout 
myoblasts (KO) were transfected with ETFDH siRNA or a control scrambled 
siRNA (Scr). (A) Schematic of PDH regulation by PDK 2/4 (B) qRT-PCR 
analysis shows decreased PDK2 and PDK 4 mRNA expression in PDK2/4 KO 
cells and decreased ETFDH mRNA with ETFDH siRNA transfection. (C) 
Western blot analysis of the inactive phosphorylated PDH (P-PDH; top panel) 
and total PDH protein expression (middle panel) show decreased PDH 
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phosphorylation in KO cells. ETFDH protein expression (bottom panel) was 
decreased in both the WT and PDK 2/4-KO cells with the ETFDH siRNA 
compared to the scrambled (Scr). (D) ATP levels (normalized to protein) 
show a significant reduction in cells with lower levels of PDH activity (WT 
Scr) with ETFDH KD further decreasing the ATP levels in WT cells.  (E) Citrate 
synthase (CS) activity is decreased in the WT cells and ETFDH KD decreases 
CS activity in both PDK2/4 KO and WT cells.  (F) ECAR/OCR values under 
basal conditions (250 µM palmitate) and after addition of 5.5 mM glucose, 
shown relative to the basal level.  
 
Discussion 
Skeletal muscle is a key tissue for determining whole-body energy usage and a 
very sensitive mirror of insulin sensitivity (DeFronzo et al., 1985).  Not surprisingly, 
muscle insulin resistance is associated with dysregulation in multiple metabolic 
pathways.  However, it remains unknown which specific metabolic reactions might 
directly cause or contribute to these phenotypes and whether they also play a 
pathogenic role in insulin resistance.  I have approached this important question 
by developing a novel in silico constraint-based FBA model of muscle metabolism.  
As with any modeling approach, flux balance analysis requires several key 
assumptions (Oberhardt et al., 2009).  Most importantly, flux balance modeling 
assumes that flux across each metabolic reaction is modulated to achieve the 
defined objective functions of the entire model.  In the case of muscle, I defined 
this objective function (goal) as both energy production (ATP+Cr-P) and storage 
(glycogen and triacylglycerols) for subsequent contraction.  In addition, flux 
balance modeling also assumes that a steady state can be achieved.  While this 
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is more readily achieved in vivo during fasting, I extended this assumption to the 
fasting-to-fed transition by examining steady-state fluxes at discrete points along 
this continuum.  To model the fasting state, which is characterized by increased 
fatty acid utilization, I allow maximal flux through CPT1.  Similarly, I relax the 
constraint I put on modifiable glucose uptake in order to mimic increased glucose 
uptake in the fed state.  Analysis of the flux transitions observed in fasted and fed 
states demonstrate that the proposed model mirrors alterations in metabolic flux in 
response to prevailing nutrient and metabolic conditions in vivo. 
I first used this model to examine the impact of increased availability of glucose 
and fatty acids, as seen in individuals with insulin resistance and T2D, on flux 
patterns.  A two-fold increase in glucose availability resulted in increased flux 
through glycolysis, glycogen storage, and TAG storage, while a two-fold increase 
in fatty acid availability increased TCA cycle, OXPHOS, glycogen storage, and 
TAG storage. With increases in both glucose and fatty acids, glucose effects 
dominate, with increases in glycolytic fluxes even in fasting states. The 
predominant effect of glucose is likely to result from its higher extracellular 
concentration (2x Gluc = 10.00 mM Gluc) as compared with fatty acids (2xFA = 
0.7675 mM FA).  I found that increasing the FA availability (7.8xFA = 3.000 mM 
FA)  to that of equal energy production of 2x Gluc did shift the metabolism to be 
primarily fatty acid focused until the 30% CPT1:70%GUmod sampling point.  As 
expected, it increased TCA cycle, OXPHOS, glycogen storage, and TAG storage 
compared to all other conditions (Figure 11).  Thus, isolated increases in 
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extracellular glucose or lipid substrates can alter metabolic flux in the model, even 
in the absence of hormonal signals.  However, it is important to note that modest 
elevations in either glucose or fatty acid availability (or both) in the model increase 
energy production, did not markedly change RQ patterns (higher in fasted AND 
lower in fed), and thus do not recapitulate the metabolic phenotypes characteristic 
of insulin resistance.   
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E. 
 
 
Figure 11. Predicted fluxes through pathways and substrate uptake, 
production, and release.  Chart shows the flux in mmol/L/time on the Y-axis.  The 
x-axis shows the flux at the discrete points from our defined fasting to fed states, as 
defined by conversely constraining the flux through CPT1 and modifiable glucose 
uptake from 0-100% of the maximum flux. The different nutrient states, defined in 
the text, are indicated by different colored lines and symbols: 1xFA/1xGluc 
(blue/diamonds), 1xFA/2xGluc (red/boxes), 2xFA/1xGluc (green/triangle), 
2xFA/2xGluc (purple/x), 2xFA/0.513xGluc (orange/star), and 7.8xFA/2xGluc 
(aqua/circle).  (A) Predicted cumulative flux through the TCA cycle, including citrate 
synthase, aconitase, isocitrate dehydrogenase-2, α-ketoglutarate dehydrogenase, 
succinyl coenzyme-A synthetase, succinate dehydrogenase, fumarase, and malate 
dehydrogenase-2 reactions.(B) OXPHOS (complexes I-V).   (C) Predicted glycogen 
storage. (D) Predicted TAG storage.  ((E) Predicted respiratory quotient (RQ). 
 
 
In order to identify reactions and pathways which modulate metabolic phenotypes 
associated with insulin resistance, I next performed in silico knockdowns (KDs) of 
each of the reactions within the model, both singly and in combination, and under 
varying extracellular nutrient conditions.  ATP+Cr-P production was sensitive to 
KDs within key energy-producing pathways (e.g. TCA and OXPHOS, NADH 
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shuttles), and in both fasting and fed states.  By contrast, reduced flux in lipid and 
branched chain amino acid oxidation pathways only reduced energy production in 
the fasting state—consistent with the more important role for these nutrients as 
energy sources in the fasting state—when glucose is limited.  KDs which reduced 
cumulative TCA cycle flux were very similar to those reducing ATP production, a 
finding likely related to the role for TCA and OXPHOS as the “final common 
pathway” for energy production.   
Conversely, relatively few KDs altered metabolic flexibility.  Interestingly, metabolic 
inflexibility was not induced by isolated impairments in TCA or OXPHOS, but was 
induced by regulators of glucose oxidative metabolism (PDH), lipid uptake and 
metabolism (CD36 and ACSL), aspartate metabolism (AST), and the transport of 
extra-mitochondrial hydrogen to the respiratory chain (glutamate-aspartate 
shuttles).  Of these, only knockdown of PDH also yielded significant reductions in 
ATP production and TCA cycle flux in the basal state.   
In general, cellular metabolism was less sensitive to in silico experimental 
knockdowns when glucose or fatty acid availability was increased.  However, no 
single knockdown (even PDH) yielded all 3 insulin resistance-related metabolic 
phenotypes under all conditions sampled.  This is intuitive given that metabolic flux 
patterns differ in each nutrient condition, and redundancy could attenuate effects 
of a single knockdown.  I thus hypothesized that defects in flux at multiple control 
reactions would be required to fully recapitulate the three insulin resistance 
phenotypes.  Consistent with this notion, KD in PDH, when combined with either 
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electron-transferring-flavoprotein dehydrogenase (ETFD) or FAT, did reduce 
ATP+Cr-P production, TCA flux, and metabolic flexibility (Figure 12).  The 
combined knockdowns also modulated flux through key pathways to yield 
additional features of insulin resistance, including reduced fatty acid oxidation, 
increased incomplete fatty acid oxidation, and decreased glycogen storage. 
 
Figure 12.  Schematic of targeted knockdowns that model phenotypes of 
insulin resistance. Knockdowns (KD; shown in green) of fatty acid transporter 
(FAT), pyruvate dehydrogenase (PDH), and electron transfer flavoprotein 
(ETFDH) recapitulated the metabolic phenotype of insulin resistance (shown in 
red), which was defined as decreased ATP+P-Cr synthesis and TCA flux and 
reduced metabolic flexibility, i.e., decreased change in respiratory quotient (RQ) in 
the fasted-to-fed transition. Additional metabolic alterations were observed 
(indicated by orange arrows), including increased glycolytic flux and release of 
non-oxidized pyruvate and parallel decrease in glycogen storage.  Fatty acid 
oxidation was decreased, while increased incomplete fatty acid oxidation resulted 
in increased release of short-chain fatty acids. 
 
The next step was to determine if one could reproduce these in silico results in 
vitro or ex vivo.  First, we investigated the expression level of the genes which 
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encode the candidate enzymes in acutely IR-induced mouse model.  Following the 
protocol established in the Melton Lab (Yi et al., 2013), Coelho isolated calf muscle 
tissue from control and IR induced mice, and performed RT-PCR for the genes in 
question.  It was found that an acute IR induction can significantly alter expression 
levels in some of the genes queried: ETFb, PDHb, and CD36.  This shows that 
under an acute induction of IR the expression of these genes are altered, and could 
lead to the dysregulated metabolism which cause the IR metabolic phenotypes.  
We next validated our in silico predictions in vivo using cultured myocytes.  We 
modulated flux through PDH and ETFDH, singly and in combination, using a 
combination of genetic ablation (of PDK2/4) and siRNA targeting ETFDH.   
Notably, we demonstrate that lower PDH activity and ETFDH KD reduced ATP 
production, reduced TCA flux (measured by citrate synthase activity) and reduced 
metabolic flexibility (approximated by change in ECAR/OCR in response to 
glucose addition).  Thus, these in vivo data demonstrate that alterations in flux 
through PDH and ETFDH can recapitulate elements of insulin resistant 
metabolism, validating the in silico predictions.    
 While these results look promising more work is necessary to elucidate the causes 
of IR phenotypes.  The PDK-KO mouse model was one option to reproduce the 
differing fluxes between the in silico PDH normal and KD conditions.  Another 
reproduction of the in silico experiments could have been to use a double siRNA 
KD scheme.  Alternatively, another approach could have been introducing PDK 
directly which inhibits PDH, providing a method to knock down PDH activity.  This 
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way, one could compare a direct in silico to in vitro/vivo KD, rather than inferring 
from a PDH overexpression model. 
While the above options were considered, the method described here was chosen 
for two main reasons.  First, as previously mentioned, it can be challenging to 
control for consistent double siRNA KDs.  Second, the goal was to reproduce the 
in silico methods as closely as possible.  The PDH was never completely knocked 
down and part of the hypothesis is that partial disruptions of PDH over long periods 
of time lead to the IR phenotypes.  
In addition to the preliminary biological validation of the in silico data, these results 
are consistent with the central regulatory role for pyruvate dehydrogenase (PDH), 
a multi-enzyme complex that converts glycolysis-derived pyruvate to acetyl-CoA.  
Activity of PDH is regulated by its coenzymes (NAD+ and coenzyme-A), post-
translational modifications (e.g., lysine acetylation (Wang et al., 2010), O-
glycosylation (Kohda et al., 2010)), and by PDH kinases and phosphatases.  
Randle first proposed a key regulatory role for PDH in metabolism;  increased fatty 
acid supply could increase ATP and NADH availability, inhibiting PDH activity and 
reducing both oxidative metabolism and uptake by muscle (Randle et al., 1963).  
Subsequent studies confirmed that PDH activity is reduced in humans with T2D or 
at risk for T2D (Mostert et al., 1999) and can also be reduced experimentally by 
lipid-induced insulin resistance (Pehmoller et al., 2012).  Less severe reductions 
in PDH activity, potentially mediated by acetylation, have recently been linked with 
metabolic inflexibility in cardiac muscle in rodents (Vadvalkar et al., 2013).  
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Conversely, activation of PDH by PDK knockout (Jeoung and Harris, 2008), 
pharmacologic inhibition of PDH kinase (Mayers et al., 2005), or exercise (Kiilerich 
et al., 2008) improves insulin resistance and glycemia.  Thus, these results build 
upon these prior findings by demonstrating that reductions in PDH flux may be a 
key contributor to deleterious metabolic phenotypes in insulin resistance.    
Electron transfer flavoprotein localizes to the mitochondrial matrix and accepts 
electrons from dehydrogenases in fatty acid, choline, and amino acid metabolism. 
These electrons are then shuttled into the electron transport chain via electron-
transferring-flavoprotein dehydrogenase (ETFDH), which is located in the inner 
mitochondrial membrane, for reduction of ubiquinone. The function of these two 
enzymes is critical for energy metabolism; mutations in either cause multiple acyl-
CoA dehydrogenase deficiency (MADD; type II glutaric aciduria) (Olsen et al., 
2007), a rare inherited disorder leading to impaired oxidation of amino acids and 
lipids and increased plasma acyl-carnitines (Rinaldo et al., 2002).   Recent 
genome-wide association studies also linked the ETFDH locus to plasma acyl-
carnitine levels in healthy individuals, suggesting a regulatory role in lipid and 
amino acid oxidative metabolism (Illig et al., 2010).  Furthermore, expression of 
ETFDH is regulated both by nutrients (up regulation after fatty acid exposure 
(Lockridge et al., 2008)) and in response to changes in insulin sensitivity.  For 
example, ETFDH is down regulated in vivo in insulin resistant mice (Sena et al., 
2009) and humans (Viguerie et al., 2012) but up regulated by treatment with the 
PPARγ agonist and insulin sensitizing drug rosiglitazone (Wilson-Fritch et al., 
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2004).  Thus, ETFDH plays a central role in lipid and amino acid oxidation; the 
model now identifies this enzyme complex as a key regulatory node which can 
interact with PDH to potentiate insulin resistance metabolic phenotypes. 
Our model also predicts that reductions in fatty acid transport flux also potentiate 
effects of PDH.  If fatty acid transport is compromised in such a “double-hit” 
scenario, intracellular lipid substrate availability would likely be reduced, limiting 
adaptive responses to maintain normal energetics. This concept is supported by 
experimental data indicating that reduced muscle fatty acid uptake (via CD36 or 
LPL) reduces mitochondrial function (Morino et al., 2012).  Moreover, fatty acid 
transporters (e.g. FATP1) can interact with and modulate PDH activity in myotubes 
(Khajah et al., 2011).    
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Conclusion 
While the conclusions drawn here are optimistic, there are limitations with the FBA 
framework.  First, in silico models cannot fully recapitulate the complexities of inter-
organ metabolism, hormonal responses, and intracellular signaling, and 
transcriptional responses which can further modulate flux within specific metabolic 
reactions.  For example, in both studies (nutrition and IR metabolism), the question 
was to determine what acute response occurs under various conditions.  It was 
assumed that the muscle had been primed for protein synthesis (i.e., after 
resistance exercise), and queried for the best acute supplementation strategy.  IN 
addition, we know that IR phenotypes present earlier in life than T2D, and 
hypothesize that it is possible that small changes at more than one critical reaction, 
maintained over many years, could indeed contribute to important differences in 
muscle energetics, nutrient partitioning, and potentially increase risk for insulin 
resistance.   
Another challenge in the application of FBA in studying metabolism of multicellular 
organisms is choosing an appropriate objective function for the organism or tissue 
(Shlomi et al., 2008).  However, muscle tissue as compared to other tissues has 
more defined states which can be modeled: contraction, recovery/growth, fasted, 
and post-absorptive, to name a few.  Because the objective was to increase 
muscle protein synthesis in response to supplementation in the first aim, the 
model’s objective function would simply be the flux through the contractile protein 
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synthesis reactions.  However, in order to elucidate the metabolism in IR, it was 
necessary to assume what the cell’s “objective” was.  In vivo, it is likely that a given 
cell has varying objective functions, affected by the prevailing hormonal, nutrient, 
or stimulated condition. Yet, I assumed that muscle tissue had evolved to store 
energy in the forms of ATP, Cr-P, glycogen, and TAG for subsequent use in 
contraction.  Under this hypothesis, modeling from a fasted to fed state produced 
results consistent to what is seen in vivo (Figure 5).   Depending on the state of 
the muscle tissue or the goal of the perturbations, one can envision other objective 
functions.  For example, one can model muscle contraction by optimization ATP 
production.  This can be done under differing oxygen availability, reflecting differing 
types of exercise: aerobic vs. non-aerobic. 
In addition to the limitations of the FBA framework, there are shortcomings to the 
specific model developed here.   The Nogiec Muscle Model (version 1.0 and 1.1) 
is less complex than previously published muscle models (Shlomi et al., 2008; 
Jerby et al., 2010; Agren et al., 2012).  However, the Nogiec Muscle model was 
curated at the level of muscle cell metabolism and includes specific protein 
synthesis for contractile protein complex, while the other models do not.  Yet, 
increasing the complexity by incorporating the specific protein synthesis into other 
published muscle models, can potentially allow one to investigate other nutrients 
and metabolites often used for supplementation. Either creating a muscle model 
de novo with increased complexity or providing better curation to the models 
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reconstructed from a general human muscle model may improve the potential of 
obtaining results more consistent with biology. 
In addition to the future work suggested in the previous chapters, the FBA 
framework could have the potential in aiding the development of personalized 
(preventative) medicine.  For example, in the case of the first application to muscle 
protein synthesis, this can be explored in many ways.  Certain types of training 
lead to muscle tissue hypertrophy, which is mostly achieved by increasing the 
contractile proteins and scaffolding proteins in the muscle tissue.  The contractile 
proteins differ slightly based on the muscle type: 1, 2a, 2x, and 2b.  However, the 
amino acid composition of these proteins is similar enough that according to the 
model, amino acid supplementation effects protein synthesis similarly.  This means 
that, similar supplementation regimes could be appropriate no matter the type of 
training goal.  However, determining if there are differences between recovery and 
growth, one can slightly alter the objective function.  For Type 1 muscle tissue 
(slow twitch), one could look at an objective function that would model increasing 
the concentration of mitochondria, while for Type 2 muscle tissue (fast twitch),  the 
contractile protein synthesis may be more appropriate.  To elucidate the 
differences even more, an objective function which incorporates a combination of 
mitochondrial proliferation and contractile muscle protein synthesis can be used to 
differentiate Type 2a, Type 2x, and Type 2b muscle tissues.  Furthermore, the 
model predicts supplementation from fasting normo-aminoacidemia and post-
absorptive states.  These profiles were obtained by averaging the profiles of 
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multiple individuals.  Perhaps, by knowing the specific amino acids levels of an 
athlete or patient, one can use this model to predict an individualized supplement 
regimen appropriate for which muscle tissue recovery is desired.  In addition, I use 
plasma concentration levels of amino acids as a proxy for amino acid flux.  Differing 
concentrations can lead to differing results.  Ultimately, one would look at which 
uptake fluxes needed to be increased to achieve the desired results. Conceivably 
this can be adapted for personalized supplementation strategies. If the 
concentrations and/or amino acid uptake fluxes of individuals were known, one 
can determine the most effective supplementation strategy to achieve the 
individual’s objective.   
Moreover, because of the non-biased sampling of all the reactions in the model, 
FBA allows for in silico experimentation not permissible in vivo and permits the 
identification of novel candidate pathways contributing to insulin resistance 
phenotypes, which may otherwise be overlooked.  Additional experimental 
validation and extension of these findings will be required in future studies.   
In summary, the aims of this dissertation were (1) to show how novel applications 
of constraint-based modeling can aid in the investigation of human nutrition and 
(2) to elucidate disruptions in metabolic networks which cause metabolic 
phenotypes associated with IR/T2D. After constructing a unique metabolic model 
of muscle metabolism incorporating metabolism from the macronutrients, I 
addressed the first aim by asking whether or not this model can predict the efficacy 
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of amino acid supplementation on contractile protein synthesis.  The results were 
qualitatively consistent with published data and showed an additional and/or 
alternative explanation as to why leucine and the other BCAAs increase muscle 
protein synthesis: BCAAs may be used as an acute energy source to support 
protein synthesis. While specific experiments would need to be done to test this 
hypothesis, these findings demonstrate potential in this framework.  To elucidate 
metabolic phenotypes associated with IR/T2D, I also used the metabolic model, 
demonstrating great flexibility with this specific model.  I incorporated reciprocal 
modulation of lipid oxidation and glucose uptake in order to model the fasted-to-
fed transition, and using this approach, I demonstrated that key metabolic 
phenotypes characteristic of human insulin resistance can be recapitulated by in 
silico experimental reductions in activity of flux through the pyruvate 
dehydrogenase complex, in combination with reductions in cellular lipid availability 
(fatty acid transport) and/or lipid or amino acid metabolism (electron-transferring-
flavoprotein dehydrogenase) (Figure 14).  The combined knockdowns also 
modulate flux through key pathways to yield additional features of insulin 
resistance, including reduced fatty acid oxidation, increased incomplete fatty acid 
oxidation, increased lactate production, and decreased glycogen storage.  I also 
demonstrate that experimental reductions in OXPHOS flux alter cellular 
energetics, as predicted, but do not alter metabolic flexibility; thus, this 
computational model predicts that isolated defects in OXPHOS flux are not likely 
to be solely responsible for insulin resistance-linked metabolic phenotypes.  In 
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addition, to validate the in silico results, two mouse models were used.  First, we 
looked at the effect of acute IR induction on the expression of the genes from the 
candidate enzymes.  It was found that in this model, the expression of at least one 
of the genes in each of the candidate enzymes was lowered, which could lead to 
the metabolic dysregulation.  To further validate that altered activity through these 
enzymes could lead to IR metabolic phenotypes, we employed a different mouse 
model.  We used a PDK 2/4-KO mouse model to investigate differing PDH flux 
independently and in combination with ETFDH siRNA.  The results show that 
cultured myotubes from cells with low PDH levels (WT) and ETFDH siRNA lead to 
decreased ATP production, citrate synthase activity, and metabolic flexibility (as 
inferred by the change in OCR/ECAR ratio), mirroring the in silico predictions.  
Together, these findings are also consistent with the concept that insulin resistance 
is not likely to arise from a single gene defect, but rather from dysregulation of 
metabolic adaptations to energy/nutrient stress at several key nodes.  More 
broadly, this analysis illustrates how computational approaches can be used to 
model metabolism and also provides a valuable resource which can be queried 
and expanded for further studies to identify novel candidate enzymes and 
pathways for type 2 diabetes pathogenesis and treatment. 
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Appendix A – Pathway Assignments 
 
Pathway Ala,_Asp,_and_
Glu 
Arg_and_Orn_
metabolism 
Arg_and_Pro_
Metabolism 
Ascorbate_and
_Alderate_Meta
bolism 
BCAA 
KEGG ID hsa00250 hsa00472 hsa00330 hsa00053 hsa00280 
Model 
Abbreviation 
ASTM 
GluDeh 
GlnSynth 
ALT 
ALDH4a1 
ASNase 
ASNSynth 
ALT 
Dr_orn 
ASTM 
ALDH3A2 
GluDeh 
GlnSynth 
ALT 
PRODH 
ALDH4a1 
GATM 
GAMT 
ASNase 
P5CS 
PYCS 
PYRCR1 
CKM 
MT_pro 
DAGL 
Fum 
AKR1A1 
ALDH3A2 
RPE 
G3PDehC 
ASTM 
CitSynth 
SucDeh-II 
ButyrlCoADeh 
EnoCoADeh-
But 
3HA-CoADeh-
But 
AcylCoAAT-But 
ALDH3A2 
DLDH 
BCAT2-val 
BCKDHB-val 
BCKADE2-val 
ACADSB 
ECHS1 
HIBCH 
HIBADH 
ALDH6A1 
PCCB 
MCEE 
MUT 
BCKDHB-ile 
BCKADE2-ile 
ECHS1 
HSD17B10_ 
ACAT1 
BCAT2-leu 
BCKDHB-leu 
BCKADE2-leu 
IVD 
MCC1-MCC2 
MGCA 
HMGCL 
OXCT 
HMGCS2 
ALT 
Acetyl-coaLeak 
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2a2hButLeak 
MT_val 
MT_ile 
MT_leu 
 
Pathway beta-alanine Butanoate Cys_and_Met_
Metabolism 
D-gln_and_D-
glu_Metabolism 
Fatty_Acid_Met
abolism 
KEGG ID hsa00410 hsa00650 hsa00270 hsa00471 hsa00071 
Model 
Abbreviation 
ASTM 
Fum 
ALDH3A2 
ECHS1 
HIBCH 
G3PDehC 
ASTM 
PyrSynth 
CitSynth 
Acon 
SucDeh-II 
Fum 
ButyrlCoADeh 
EnoCoADeh-
But 
3HA-CoADeh-
But 
AcylCoAAT-But 
ACSM-But 
ECHS1 
ACAT1 
HMGCL 
OXCT 
HMGCS2 
ILVBL 
ASTM 
Fum 
AKR1A1 
SDS 
CBS 
CTH 
AdoHcyase 
MTR 
AdoMet 
 
 
GluDeh 
Spont_Glu 
GLN_Elim 
MT_glu 
SucDeh-II 
PalTK 
CPT1B-CHKL 
CPT2 
AcylCoADeh 
EnoCoADeh 
3HA-CoADeh 
AcylCoAAT 
AcylCoADeh-
18-c 
EnoCoADeh-
18c 
3HA-CoADeh-
18c 
AcylCoAAT-18c 
AcylCoADeh-
14-c 
EnoCoADeh-
14c 
3HA-CoADeh-
14c 
AcylCoAAT-14c 
AcylCoADeh-
12-c 
EnoCoADeh-
12c 
3HA-CoADeh-
12c 
AcylCoAAT-12c 
AcylCoADeh-
10-c 
EnoCoADeh-
10c 
3HA-CoADeh-
10c 
AcylCoAAT-10c 
AcylCoADeh-8-
c 
EnoCoADeh-8c 
3HA-CoADeh-
8c 
AcylCoAAT-8c 
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AcylCoADeh-6-
c 
EnoCoADeh-6c 
3HA-CoADeh-
6c 
AcylCoAAT-6c 
ButyrlCoADeh 
EnoCoADeh-
But 
3HA-CoADeh-
But 
AcylCoAAT-But 
ACSM-But 
ASCM-5c 
ASCM-6c 
ACSM-10c 
CPT1B-CHKL 
CPT2 
AcylCoADeh-9-
c 
EnoCoADeh-9c 
3HA-CoADeh-
9c 
AcylCoAAT-9c 
AcylCoADeh-7-
c 
EnoCoADeh-7c 
3HA-CoADeh-
7c 
AcylCoAAT-7c 
AcylCoADeh-5-
c 
EnoCoADeh-5c 
3HA-CoADeh-
5c 
AcylCoAAT-5c 
AKR1A1 
ALDH3A2 
ECHS1 
ACAT1 
GCDH 
Acetyl-coaLeak 
 
Pathway Folate_Metaboli
sm 
Fructose_and_
mannose_meta
bolism 
Galactose_Met
abolism 
Glutathione_me
tabolism 
Glyc,_Ser,_Thr
e 
KEGG ID hsa00790 hsa00051 hsa00052 hsa00480 hsa00260 
Model 
Abbreviation 
AKR1A1 
DHFR 
QDPR 
Hex 
PFK 
FBP 
Ald 
Hex 
PFK 
AKR1A1 
PGM1 
IsoDehnadph 
G6PD 
PGD 
GCL 
G3PDehC 
Fum 
AKR1A1 
GLYCTK 
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TPI 
G3PDehC 
AKR1A1 
UGP2 GSS 
GSR 
GlutathLeak 
glutathxport 
DLDH 
SDS 
CBS 
CTH 
GATM 
GAMT 
SHMT 
PHGDH 
PSA 
PSPH 
 
Pathway Glycerolipid Glycerophosph
olipid 
Glycolysis Glyocylate_and
_Dicarboxylate_
metabolism 
Histidine_Metab
olism 
KEGG ID hsa00561 hsa00564 hsa00010 hsa00630 hsa00340 
Model 
Abbreviation 
LPL 
MAGL 
Hex 
Acon 
Fum 
GK 
GPAT4 
ABHD5 
DAGZ-DAGK6 
DGAT1 
AKR1A1 
ALDH3A2 
GLYCTK 
St_TAG 
DAGL 
G3PDehC 
GPAT4 
ABHD5 
DAGZ-DAGK6 
BCAT-ile 
St_TAG 
Hex 
PGI 
PFK 
FBP 
Ald 
TPI 
D3PDeh 
PGK 
PGM 
Eno 
PyrK 
PEPCarbK 
PyrSynth 
AKR1A1 
ALDH3A2 
DLDH 
PGM1 
G3PDehC 
CitSynth 
Acon 
MalDehM 
ACSM-14c 
ACSM-18c 
AKR1A1 
GLYCTK 
ASNase 
TPI 
AKR1A1 
ALDH3A2 
GAMT 
HAL 
FLJ31300 
MGC35366 
FTCD1 
ASNase 
 
Pathway Ketone_Metabo
lism 
Lysine Nitrogen_metab
olism 
Once_Carbon_
Pool_by_folate 
OxPhos 
KEGG ID hsa00072 hsa00310 hsa00910 hsa00670 hsa00190 
Model 
Abbreviation 
CitSynth 
AcylCoAAT-But 
ACAT1 
HMGCL 
OXCT 
HMGCS2 
AKGDeh 
EnoCoADeh-
But 
3HA-CoADeh-
But 
AcylCoAAT-But 
ECHS1 
ACAT1 
AASS 
aAASADeh 
GluDeh 
GlnSynth 
CTH 
SHMT 
HAL 
ASNase 
ASNSynth 
GLN_Elim 
ALA_Elim 
G3PDehC 
MTR 
SHMT 
MTHFR 
DHFR 
FTCD1 
FTCD2 
FT 
ASNase 
PYRCR1 
SucDeh-II 
NADHDeh-I 
UCytC-III 
CytCO-IV 
ATPSynth-V 
AMP_ADPsuppl
y 
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KATII 
GCDH 
ASNase 
lysdeg 
MT_lys 
 
Pathway Pentose_and_gl
ucouronate_inte
rconversions 
Pentose_Phosp
hate 
Phe,_Tyr,_Try_
Metabolism 
Phe_metabolis
m 
Propanoate 
KEGG ID hsa00040 hsa00030 hsa00400 hsa00360 hsa00640 
Model 
Abbreviation 
TPI 
ALDH3A2 
UGP2 
RPE 
PGI 
PFK 
FBP 
Ald 
AKR1A1 
PGM1 
G6PD 
PGLS 
PGD 
RPE 
RPIA 
TKT1 
TKT2 
TALDO 
RBSK 
ASTM 
Fum 
AKR1A1 
PAG 
ASTM 
PalTK 
AKR1A1 
ALDH3A2 
ALT 
PAG 
G3PDehC 
ASTM 
SunCoaSynth 
Fum 
ALDH3A2 
ECHS1 
HIBCH 
ALDH6A1 
PCCB 
MCEE 
MUT 
ECHS1 
ACAT1 
ACAS2 
 
Pathway Pyruvate_meta
bolism TCA_Cycle Tryptophan Tyrosine 
AminoAcid_Upt
ake 
KEGG ID hsa00620 hsa00020 hsa00380 hsa00350 n-a 
Model 
Abbreviation 
PyrK 
PEPSynth 
PEPCarbK 
PEPCarbl 
LacDeh 
G3PDehC 
PyrSynth 
CitSynth 
MalDehM 
AcylCoAAT-But 
ALDH3A2 
DLDH 
ACAT1 
PEPCarbK 
PyrSynth 
CitSynth 
Acon 
IsoDeh 
IsoDehnadph 
AKGDeh 
SunCoaSynth 
SucDeh-II 
Fum 
MalDehM 
DLDH 
Acetyl-coaLeak 
MCT 
AKGDeh 
EnoCoADeh-
But 
3HA-CoADeh-
But 
AcylCoAAT-But 
ALDH3A2 
ECHS1 
ACAT1 
ALT 
GCDH 
WARS 
ASTM 
AKR1A1 
GAMT 
EAA_arg 
EAA_his 
EAA_ile 
EAA_leu 
EAA_lys 
EAA_met 
EAA_phe 
EAA_thr 
EAA_trp 
EAA_val 
NEAA_ala 
NEAA_asn 
NEAA_asp 
NEAA_cys 
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NEAA_glu 
NEAA_gln 
NEAA_gly 
NEAA_pro 
NEAA_ser 
NEAA_tyr 
 
Pathway ATP_Metabolis
m 
Carnitine_Trans
port 
Cellular_Excha
nge Creatine 
MacroNutrient_
Exchange 
KEGG ID n-a n-a n-a n-a n-a 
Model 
Abbreviation 
Obj_atp 
AMP_ADPsuppl
y 
SLC22A5-
OCTN2 
SLC25A20-
CACT 
12DAG 
GLUT4 
MCT4 
MCT_pyr 
FAT-CD36 
FATprop 
FATbut 
FAT5c 
FAT6c 
FAT8c 
FAT9c 
FAT10c 
FAT12c 
FAT14c 
FAT18c 
Alc_glyc 
COA 
Xport_rib 
Dr_akg 
Dr_oaa 
CKM 
Spont_CrP 
Nut_cr 
Dr_cr 
Ex_ins 
Ex_gluc 
Ex_lac 
Ex_pyr 
Ex_pal 
Ex_prop 
Ex_but 
Ex_5c 
Ex_6c 
Ex_8c 
Ex_9c 
Ex_10c 
Ex_12c 
Ex_14c 
Ex_18c 
Ex_glyc 
Ex_tag 
Ex_dag 
Ex_mag 
Ex_akg 
Ex_oaa 
Ex_rib 
 
Pathway MicroNutrient_E
xchange 
Protein_Synthe
sis Glycogen NAD_NADH FAD_FADH 
KEGG ID n-a n-a n-a n-a n-a 
Model 
Abbreviation 
Nut_o2 
Nut_co2 
Nut_h2o 
Nut_p 
Nut_hco3 
Nut_coa 
Nut_carn 
Nut_dhf 
YARS 
WARS 
TARS 
LARS 
IARS 
KARS 
AARS 
VARS 
Hex 
PGI 
ATP2UTP 
UDP2ADP 
PGM1 
UGP2 
mGYG 
mGYS1 
D3PDeh 
LacDeh 
MalDehC 
G3PDehC 
PyrSynth 
IsoDeh 
IsoDehnadph 
AKGDeh 
G3PDehM 
SucDeh-II 
ETFUO 
AcylCoADeh 
AcylCoADeh-
18-c 
AcylCoADeh-
14-c 
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MARS 
SARS 
DARS 
GARS 
PARS 
CARS 
EPRS 
QARS 
RARS 
FARS 
HARS 
NARS 
ACT 
MYOHC1-2x 
MYOHC2a 
MYOHC2b 
MYOLCk 
MYOLCp 
MYO1-2x 
MYO2a 
MYO2x 
MYO2b 
TMN1 
TMN2 
DIM-TMN1 
DIM-TMN2 
TPNC1 
TPNC2 
TPNI1 
TPNI2 
TPNT1 
TPNT2 
TPN1 
TPN2 
CONTR-
COMP1 
CONTR-
COMP2a 
CONTR-
COMP2x 
CONTR-
COMP2b 
Str_CONTR-
COMP1 
Str_CONTR-
COMP2a 
Str_CONT-
COMP2x 
Str_CONTR-
COMP2b 
UDP2ADP 
mGYS1 
ATP2UTP 
MalDehM 
NADHDeh-I 
3HA-CoADeh 
3HA-CoADeh-
18c 
3HA-CoADeh-
14c 
3HA-CoADeh-
12c 
3HA-CoADeh-
10c 
3HA-CoADeh-
8c 
3HA-CoADeh-
6c 
3HA-CoADeh-
9c 
3HA-CoADeh-
7c 
3HA-CoADeh-
5c 
AKR1A1 
ALDH3A2 
DLDH 
HIBADH 
ALDH6A1 
HSD17B10_ 
GluDeh 
AASS 
aAASADeh 
lysdeg 
ALDH4a1 
MTHFR 
DHFR 
FT 
PHGDH 
PYCS 
PYRCR1 
QDPR 
G6PD 
PGD 
GSR 
Recycle_nadp 
AcylCoADeh-
12-c 
AcylCoADeh-
10-c 
AcylCoADeh-8-
c 
AcylCoADeh-6-
c 
ButyrlCoADeh 
AcylCoADeh-9-
c 
AcylCoADeh-7-
c 
AcylCoADeh-5-
c 
ACADSB 
IVD 
PRODH 
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Pathway Mit_Shuttle All_Pathways 
KEGG ID n-a hsa01100 
Model 
Abbreviation 
Dr_akg 
Dr_oaa 
MalDehC 
ASTC 
G3PDehC 
Mal-AKGEX 
Glu-AspEx 
ASTM 
G3PDehM 
MalDehM 
All reactions in the 
model 
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